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Vitamin C status, oxidative stress, hyperglycaemia and endothelial function in 
critically ill patients with septic shock: an observational study 
ABSTRACT 
Septic shock is associated with oxidative stress, reduced levels of plasma vitamin C 
and stress hyperglycaemia – all factors that may influence endothelial, and therefore, 
organ function. Vitamin C is an important antioxidant in human plasma; and it has 
been implicated in maintaining normal endothelial function during oxidative stress. 
The vitamin C status of critically ill patients in South African ICUs has not been well 
investigated; neither has the relationship between vitamin C status, oxidative stress, 
hyperglycaemia and endothelial function been studied in this patient group. 
In a prospective, cross-sectional study investigating these factors in critically ill 
patients with septic shock on inotropic support, serial blood samples from 25 patients 
were taken at days zero and one, following inotrope initiation, and on day seven after 
inotrope cessation. These samples were analysed for plasma vitamin C, thiobarbituric 
acid-reactive substances (TBARS) – as a biomarker of oxidative stress – and soluble 
vascular cell adhesion molecule-1 (sVCAM-1), and E-selectin, as markers of 
endothelial dysfunction. The plasma glucose to vitamin C ratios were also calculated. 
Daily clinical measures in the patients included Sequential Organ Failure Assessment 
(SOFA) score, mean arterial blood pressure, blood glucose, fluid balance and 
inotropic support. The clinical outcomes were recorded. 
Septic shock patients had low levels of plasma vitamin C at baseline, which persisted 
up to day seven – after the resolution of septic shock. There was also evidence of 
oxidative stress, marked by increased levels of plasma TBARS. At the baseline, 
markers of oxidative stress were statistically significantly higher in non-survivors 
than in the survivors of septic shock. Plasma glucose to vitamin C ratios were raised 
on all the study days. In non-survivors, the maximum blood glucose correlated 
negatively with vitamin C levels.  
The bio-markers of endothelial dysfunction (sVCAM-1 and E-selectin) were raised 
at the baseline. Soluble VCAM-1 levels fell significantly on day one, and were 
normalized on day seven; while the E-selectin levels were raised on day one; and 
they further increased significantly up to day seven. Oxidative stress and endothelial 
dysfunction were associated with increased organ dysfunction, measured by the 
SOFA score. Increased oxidative stress was associated with both increased duration 
of inotropic support, and the increased requirements for intravenous fluids.  
This study has, therefore, demonstrated that low vitamin C status and oxidative stress 
persisted up to seven days after the resolution of septic shock. Increased oxidative 
stress was associated with increased endothelial damage; and both of these factors 




that increased oxidative stress was associated with increased intravenous fluid, and 
with prolonged inotrope requirements. 
The study confirms low vitamin C status and the association of oxidative stress with 
endothelial dysfunction and multiple organ failure in septic shock. It discusses the 
need for further studies to explore the impact of high dosage vitamin C 
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CHAPTER 1: LITERATURE REVIEW  
 
1.1. Critical illness 
Critical-care medicine is the management of severe illness associated with organ 
dysfunction, such as acute respiratory failure, in patients who are at risk of imminent 
death (Adhikari et al., 2010; Ehlenbach et al., 2010). In the early days of intensive-
care medicine, the emphasis was mainly on the mechanical ventilation of patients, 
such as those suffering from poliomyelitis (IBSEN, 1954).  
 
The discipline has now advanced in the understanding of the pathophysiology of 
dysfunctional organs and the development of the respective supportive technology 
(Adhikari et al., 2010). Septic shock is one of the common disease processes in 
critical illness; and it is a major cause of morbidity and mortality worldwide (Roman-
Marchant et al., 2004). 
 
1.2. Septic shock 
Table 1 describes the definitions of systemic inflammatory response syndrome 
(SIRS), sepsis, severe sepsis and septic shock. Sepsis is defined as SIRS that is 
characterized by abnormalities in two or more clinical features, including body 
temperature, heart rate, respiratory function and peripheral leukocyte count, in the 
presence of, or as a result of, suspected or proven infection (Bone et al., 1992).  
 
When severe, sepsis can be complicated by the presence of cardiovascular organ 
dysfunction, acute respiratory distress syndrome or other organ dysfunction. Septic 
shock occurs when severe sepsis is complicated by acute circulatory failure, which is 
characterized by persistent arterial hypotension – despite adequate fluid resuscitation, 
or by tissue hypo-perfusion manifested by a raised lactate concentration that is 
unexplained by other causes (Dellinger et al., 2013).  
 
It is important to note that 40% of severe septic cases progress to septic shock 
(López-Bojórquez, Dehesa & Reyes-Terán, 2004). Such patients require ICU 
management including organ support; and the condition has increased morbidity and 




impaired physical or neurocognitive functioning, mood disorders, a low quality of 
life; and they have the additional risk of mortality (Angus et al., 2001). 
 




Two or more of the following criteria:  
- Temperature < 36 °C or > 38 °C  
- Heart rate > 90 beats per minute 
- Respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg  
- White blood cell count > 12000 x10
9
/L < 4000 x10
9
/L, or > 
10% immature (band) forms 
Sepsis 
Documented infection together with two or more SIRS criteria 
above 
Severe Sepsis Sepsis associated with organ dysfunction 
Septic Shock 
Sepsis with refractory hypotension or hypoperfusion 
abnormalities in spite of adequate fluid resuscitation  
Derived from Bone RC, Balk RA, Cerra FB, et al. (June 1992)  
 
Currently, guidelines on the management of severe sepsis in ICU include: Initial 
resuscitation with fluids or blood products, appropriate antibiotic therapy (preferably 
within the first hour of recognition of septic shock), diagnosis of the cause of the 
sepsis and controlling the source of sepsis, further infection prevention and hospital-
based performance-improvement efforts in the management of severe sepsis 
(Dellinger et al., 2013).  
 
Other supportive measures include vasopressor and inotropic-vasopressor therapy, 
glycaemic control, prophylaxis for deep-vein thrombosis, prophylaxis for stress 
ulceration in patients with risk of bleeding, oxygen supplementation and mechanical 
ventilation, as well as other organ-support treatments, as may be indicated (Dellinger 
et al., 2013). Despite the advances in its management, septic shock is still associated 
with high morbidity and mortality. Statistics show that 20% – 30% of patients with 
septic shock still die – even in settings where aggressive antibiotic therapy and 
advanced life support are provided (Kethireddy & Kumar, 2012; Labelle et al., 
2012). This could possibly be due to the complex pathophysiology associated with it; 





1.2.1. Pathophysiology and consequences of septic shock 
The pathogenesis of septic shock that leads to multi-organ dysfunction is 
multifactorial and complex (López-Bojórquez, Dehesa & Reyes-Terán, 2004). Figure 
1 below describes the steps that occur in uncontrolled sepsis – leading to septic 
shock. 
 
The cascade of events begins with a focus of infection (step 1, Figure 1), which could 
be in any organ where there is a release of protein fragments or immunogens from 
viruses, bacteria or fungi into the blood stream (Crowley, 1996). The causative 
organism of the infection may then enter the blood stream, where the  innate immune 
system recognises evolutionarily conserved structures on pathogens, termed 
pathogen-associated molecular patterns (PAMPs) (Mogensen,T.H., 2009) (step 2 
Figure 1). PAMPs are recognised through a limited number of germ line-encoded 
pattern recognition receptors (PRRs) including the family of Toll-like receptors 
(TLRs) (Mogensen, T.H., 2009). Several studies, mainly focusing on gram-negative 
bacterial sepsis have shown that lipopolysaccharide is shed from the cell wall of 
pathogens, such as E. coli (Bayston & Cohen, 1990; Glauser et al., 1991; Rietschel & 
Brade, 1992). However, lipoteichoic acid from gram-positive bacteria and 
ergosterols from fungi have also been described (López-Bojórquez, Dehesa & Reyes-
Terán, 2004). 
 
The lipid A portion of the lipopolysaccharide molecule is the part involved in the 
binding of the molecule to virtually all cells once they are released into the blood. 
(Bayston & Cohen, 1990; Crowley, 1996; Glauser et al., 1991; Rietschel & Brade, 
1992). As depicted in step 3 of Figure 1, the binding of the polysaccharides to the 
endothelium, monocytes or macrophages induces the production of chemical 
mediators in the pathogenesis of septic shock. When activated, the 
monocyte/macrophage system secretes a variety of soluble factors, such as peptide 
hormones with pro-inflammatory activity and inflammatory cytokines [tumour-
necrosis factor-alpha (TNF-α), interleukin 1-beta (IL-1β) and interleukin- 6 (IL-6)] 






Figure 1. Sequence of pathogenetic steps leading from nidus of infection to cardiovascular dysfunction and 
shock during human sepsis 




It is these cytokines that directly or indirectly cause serial changes at cellular levels 
in the vascular and immune system to begin with – and then to the rest of the tissues 
(Fantuzzi et al., 2000). Production of the endogenous mediators following sepsis and 
sepsis itself affects the heart and the systemic circulation. 
 
 In the heart, sepsis-induced myocardial dysfunction is common, and corresponds to 
the severity of sepsis, as shown in step 4 of Figure 1 (Furian et al., 2012). The 
mechanisms of this process include the attenuation of the adrenergic response at the 
cardiomyocyte level, the alterations of intracellular calcium trafficking, and the 
blunted calcium sensitivity of contractile proteins (Rudiger & Singer, 2013). These 
changes are mediated by cytokines (Rudiger & Singer, 2013). In vitro studies have 
supported this by showing that serum from septic patients decreases myocyte 
contractile function; and these studies have also indicated the presence of 
myocardial-depressant mediators, including nitric oxide (NO) (Kumar et al., 2001; 
Lupia et al., 2010; Merx & Weber, 2006).  
 
On the systemic circulation, septic shock is associated with the maldistribution of 
intravascular blood volume (Crowley, 1996; Nduka & Parrillo, 2011). This could be 
explained in part as the result of generalised vasodilation that results from the hypo-
responsiveness of blood vessels to the sympathetic system – leading to the loss of 
vascular tone (Biesalski & McGregor, 2007; McGregor & Biesalski, 2006). The 
reduced responsiveness to epinephrine and norepinephrine could be explained by 
three possible mechanisms. Firstly, there is the altered affinity of receptors to these 
hormones (Boyd, Stanford & Chernow, 1989). Secondly, there is a reduction in the 
number of adrenergic receptors – as a response to the activity of TNF-α (Silverman 
et al., 1993). Thirdly, there is evidence suggesting that there are intracellular defects 
that render the response to the hormones dysfunctional (Boyd, Stanford & Chernow, 
1989; Silverman et al., 1993).  
 
The vasodilation is further enhanced by the production of abnormally high levels of 
NO by the endothelial cells, through the inducible Nitric Oxide synthase system 
(iNOS). The iNOS is mediated by nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), and is induced under septic conditions (Tyml, Li & 




results of the vasodilation are an increased cardiac output, decreased perfusion in 
some organs, lowered effective blood volume, tachycardia and hypotension 
(Crowley, 1996). These are the clinical features observed in septic shock. Studies 
using animal models of sepsis have confirmed that the effects of excessive NO 
production contributes – not only to the generalised hypotension – but also to the 
myocardial dysfunction that occurs in sepsis (Rudiger & Singer, 2007).  
 
One of the important effects of cardiovascular insufficiency (steps 5 and 6 of Figure 
1) is multisystem-organ failure, following the generalised hypotension and reduced 
tissue perfusion. This leads to the increased morbidity; and although some patients 
survive, up to 50% do not survive septic shock (Labelle et al., 2012). 
 
Apart from the mechanisms in the development of septic shock, as described above, 
the production of free radicals, which contribute to oxidative stress, is also an 
important pathophysiological phenomenon in severe sepsis.  
 
1.3. Free radical formation, antioxidants and oxidative stress 
 
1.3.1. Free radical formation and antioxidants 
Free radicals are defined as molecules possessing one or more unpaired electrons; 
but they can also be seen as a fragment of a molecule (Halliwell, 1994). Important 
free radicals in pathological processes include oxygen free radicals, and reactive 
oxygen species (ROS) i.e. superoxide anion, hydrogen peroxide and the hydroxyl 
radical, as well as the reactive nitrogen species (RNS) e.g. nitric oxide and 
peroxynitrite, a product of the reaction between superoxide and nitric oxide 
(Halliwell, 1997; Halliwell, 2012). 
 
Under normal homeostasis, free radicals may be generated in regulated amounts to 
take part in some processes, such as in proliferative signalling; and they may also be 
produced by phagocytes – as a measure of the host’s defense against infection 
(Babior, 1978). In other cases, free radicals may also be incidental products, as in the 
case of the mitochondrial electron-transport chain, where some electrons may escape 
from electron carriers directly to the oxygen forming superoxide radical (Berger, 




damage biologically relevant molecules, such as DNA, RNA, proteins, carbohydrates 
and the unsaturated fatty acids of the cell membranes (Berger, 2005; Goodyear-
Bruch & Pierce, 2002) thereby triggering cell injury and tissue dysfunction (Lovat & 
Preiser, 2003). The potential harmful effects of these free radicals are opposed by 
antioxidant mechanisms. 
  
Antioxidants are substances, which inhibit or delay the oxidation, while present in 
small amounts (Halliwell & Gutteridge, 1990). Antioxidants scavenge free radical 
intermediates and inhibit other oxidation reactions by being oxidized themselves, so 
antioxidants are often reducing agents (Sies & Stahl, 1995). Antioxidants exist in two 
categories, namely non-enzymatic and enzymatic systems. Non-enzymatic 
antioxidants include micro-nutrients, such as vitamin C, vitamin E and beta-carotene, 
but also endogenous molecules, such as glutathione, bilirubin and albumin (Berger, 
2005). Enzymatic antioxidant systems include superoxide dismutase (SOD), catalase 
and glutathione peroxidase (GPx), respectively, where trace elements, such as 
copper, manganese, zinc, iron and selenium are required for their activity (Lovat & 
Preiser, 2003). When oxidants are produced in excess, antioxidants cannot quench all 
the free radicals that are produced; and consequently, oxidative stress occurs. 
 
1.3.1.1. The micronutrient antioxidant vitamin C 
Vitamin C is an important antioxidant micronutrient. It is a major water-soluble 
antioxidant that works as the first line of defence against free radical action in plasma 
and whole blood. It is an essential nutrient in humans and other animals, due to the 
absence of the enzyme l-gulonolactone oxidase required for its synthesis from 
glucose (Linster & Schaftingen, 2007). The term vitamin C refers to both ascorbic 
acid and dehydroascorbic acid (DHA) (Seno et al., 2004).  
 
The biological functions of ascorbic acid as an antioxidant are based on its ability to 
provide reducing equivalents for a variety of biochemical reactions. The vitamin 
readily scavenges ROS and RNS (e.g., hydroxyl, peroxyl, superoxide, peroxynitrite, 
and nitroxide radicals) as well as singlet oxygen and hypochlorite (Buettner, 1993; 
Halliwell & Whiteman, 1997; Sies & Stahl, 1995). Ascorbic acid is not only a potent 
hydrophilic antioxidant; but is also essential in the regeneration of the oxidized form 




Wessner, 2004). Normal vitamin C levels have been found to be also essential for 
normal endothelial function, which is disrupted in severe sepsis (Wilson, 2009). 
 
The requirement for vitamin C is increased in critical illness – as it is consumed 
following irreversible biochemical reactions (Berger, 2007). Increased oxidative 
stress overwhelms the available vitamin C supply, thereby causing a deficiency. 
Vitamin C concentration is reduced both in the plasma and endothelial cells in severe 
sepsis (Seno et al., 2004; Wilson, 2009). This will be discussed further in a 
subsequent section of this literature review. 
 
1.3.2. Oxidative stress  
Oxidative stress is a serious imbalance between free radicals and antioxidants 
(Halliwell, 1997). This occurs when there is increased free radical generation or 
decreased antioxidant protection with failure to prevent oxidative damage.  
 
Oxidative stress can be measured. Reactive oxygen species have a very short half-
life; and as such, obtaining a measure of oxidative stress is mainly dependent on the 
by-products of lipid, DNA and protein peroxidation (Berger & Chioléro, 2007). 
Thiobarbituric acid-reactive substances (TBARS) are markers of lipo-peroxidation 
which can be measured in human plasma (Goode et al., 1995; Takeda et al., 1984). 
 
Intense intravascular oxidative stress occurs in critical illness – especially in severe 
sepsis; and it arises from the enormous production of free radicals in a non-regulated 
fashion under conditions of inadequate anti-oxidative defences (MacDonald, 2003; 
Galley et al., 1997; Doise et al., 2008). Uncontrolled oxidative stress has been 
associated with organ dysfunction and multi-organ failure, leading to increased 
morbidity and mortality (Biesalski & McGregor, 2007; Heyland et al., 2013).  
Although critical illness has generally been associated with oxidative stress, patients 
that satisfy the systemic inflammatory response syndrome (SIRS) criteria, such as 
severe sepsis, have in particular been shown to have higher levels of oxidative stress 
and reduced total antioxidant capacity (Alonso de Vega et al., 2002; Ogilvie et al., 
1991). Goode et al. (1995) demonstrated earlier that septic shock was associated with 
a marked decrease in circulating concentrations of antioxidant micronutrients; and 




These results have been supported by other studies (Andresen et al., 2008; Galley, 
Davies & Webster, 1996; Metnitz et al., 1999; Motoyama et al., 2003). The study by 
Goode et al. (1995), however, did not look at the relationship of oxidative stress to 
endothelial dysfunction, a phenomenon that has been understood to mediate the 
pathophysiology of organ dysfunction in severe sepsis (Edul et al., 2012). 
Furthermore, this study did not measure the vitamin C status, a potent antioxidant 
that promotes normal endothelial function in severe sepsis (Wilson, 2013). This is an 
area that, therefore, requires further exploration. 
 
Organ dysfunction, which is a complication of severe sepsis, has been associated 
with further increases in oxidative stress (Himmelfarb et al., 2004), even more so in 
those with multi-organ failure (Motoyama et al., 2003). Ware et al. (2011) confirmed 
these findings and further demonstrated that increased oxidative stress is associated 
with renal, hepatic, and coagulation failure in critically ill patients with severe sepsis. 
However, their results did not show any significant difference in the levels of F2-
isoprostanes, as markers of oxidative stress, between survivors and non-survivors. 
 
Evidence shows that severe sepsis also predisposes the endothelial cell surface to 
oxidative stress. In a prospective, observational study in which endothelial cells were 
induced to produce ROS, and to analyse whether ROS production was correlated to 
severity of septic shock, Huet et al. (2007) demonstrated that plasma from septic 
shock patients caused naive human umbilical vein endothelial cells (HUVEC) to 
produce ROS. This study also showed that ROS production correlated with mortality 
and with the Sequential Organ Assessment Failure (SOFA) score. This illustrates that 
the endothelial cells play a significant role in the formation of ROS in severe sepsis – 
thereby suggesting that this could be part of the pathogenesis – leading to endothelial 
and microcirculatory dysfunction.  
 
There is agreement in the literature concerning oxidative stress and its association 
with septic shock (Andresen et al., 2008; Berger & Chioléro, 2007; Wilson, 2013). 
However, while most studies showed a decrease in plasma vitamin C in septic shock, 
the concentration of other micronutrient antioxidants, such as vitamin E, has been 
inconsistently reported. Andresen et al. (2008) found that there was an associated 




vitamin E status of the patients was similar to that of the healthy control group. Also, 
while an increase in TBARS levels was associated with a decrease in vitamin C 
levels at 24 hours and 72 hours, and day 7, there was no significant change in the 
vitamin E plasma levels in this study (Andresen et al., 2008).  
 
This study also showed that the plasma vitamin C in survivors only normalised at 
three months. The data from Andresen et al. suggest that vitamin C is one of the 
antioxidant micronutrients with high consumption levels during the first week of 
sepsis; and that these levels only normalise between one week from the onset of 
sepsis and three months. This could possibly be related to the participation of vitamin 
C in restoration of endothelial function in severe sepsis – rather than just being an 
antioxidant (Han et al., 2010; Tyml, Li & Wilson, 2008; Wilson, 2009; Wu, Wilson 
& Tyml, 2004; Wu et al., 2007; Zhou et al., 2012).  
 
The other challenge that complicates the management of septic shock is stress 
hyperglycaemia. 
 
1.4. Hyperglycaemia and its effects in critical illness 
Clinically, critical illness is associated with a transient elevation of blood glucose 
levels in the absence of diabetes mellitus (including sepsis). This is termed stress 
hyperglycaemia (Dungan, 2009); and control of blood glucose levels in such clinical 
conditions is a challenge (Smith, 2000). Stress hyperglycaemia has been associated 
with poor clinical outcomes of critically ill patients. High maximum blood glucose 
levels during their stay in ICU have been correlated with increased morbidity, 
specifically infection, and mortality (Christiansen et al., 2004). Mortality rate in 
newly diagnosed hyperglycaemic patients was found to be six times higher than 
those with known diabetes, and therefore chronic, pre-existing hyperglycaemia 
(Umpierrez et al., 2002).  
 
These findings have been supported by other research findings (Egi et al., 2008; 
Leonidou et al., 2007). Acute hyperglycaemia possibly influences clinical outcome 
by, but not only limited to, its contribution to oxidative stress and endothelial 





Van den Berghe et al., (2001) first demonstrated in their randomised controlled-trial 
of tight glucose control (4.4–6.2mmol/l) in adult ICU patients prevented excessive 
morbidity and mortality, compared with those tolerating stress hyperglycaemia – up 
to 12mmol/l. And several other studies have confirmed and supported this finding 
(Hirsch et al., 2002; Ellger & Van den Berghe, 2009; Van den Berghe et al., 2006; 
Van den Berghe, 2013). Another randomised, controlled study however favoured 
control of blood glucose levels between 7.8mmol/L and 10mmol/L (The NICE-
SUGAR Study Investigators, 2009). It has thus been recommended in a review of 
such studies that blood glucose be maintained at levels as close to normal as possible, 
without evoking unacceptable fluctuations, hypoglycemia, and hypokalemia (Van 
den Berghe, 2009). 
 
In critical care, the use of drugs such as steroids has also been shown to cause 
hyperglycaemia, because they reduce insulin sensitivity (Oyer, Shah & 
Bettenhausen, 2006); and consequently, the incidence of steroid-induced 
hyperglycaemia is high (Fong & Cheung, 2013). 
 
Variability of glucose levels seems to be more deleterious than persistent 
hyperglycaemia. Repetitive postprandial fluctuations in glucose concentration have 
been shown to evoke monocyte adhesion to endothelial cells to a greater extent than 
that in diabetic rat models with stable hyperglycaemia. Suppression of such 
fluctuations efficiently suppressed leucocyte adhesion to the aortic endothelium 
(Azuma et al., 2006). However, this study group did not find any associated increase 
in the expression of mRNA for soluble vascular cell-adhesion molecule 1 (sVCAM-
1) as a marker of endothelial dysfunction.  
 
An in vitro study showed that endothelial cells exposed to intermittently elevated 
glucose levels could be associated with the overproduction of ROS, suggesting that 
in vivo glucose fluctuation may be involved in the development of oxidative stress 
and vascular injury (Quagliaro et al., 2003). This study group further reported that 
the exposure of endothelial cells to hyperglycaemic conditions, and even more so 
those with marked variations of glucose levels, increased the expression of several 
adhesion molecules, including soluble vascular cell adhesion molecule-1 and E-




evidence for endothelial damage and activation from an insult (Chen et al., 2011; 
Cook-Mills, Marchese & Abdala-Valencia, 2011). However, these are only in vivo 
and animal-based studies. What have clinical studies shown on this topic? 
 
In a case-control study, it was shown that acute hyperglycaemia in both type 1 
diabetic and healthy individuals induces an inflammatory response that may be 
accompanied by oxidative stress (Gordin et al., 2008). Another clinical study 
reported decreased endothelial function using flow-mediated dilatation technique and 
increased urinary markers of oxidative stress in consistently high and fluctuating 
glycaemic conditions (Ceriello et al., 2008). Flow-mediated dilatation technique is 
designated as an endothelium-dependent process that reflects the relaxation of a 
conduit artery when exposed to increased flow and, thereby, increased shear stress 
(Moens et al., 2005). In humans, flow-mediated dilatation is usually assessed in large 
peripheral conduit arteries (brachial, radial, and femoral), imaged with adequately 
powered ultrasound equipment compatible with vascular 2D, colour flow, and pulse-
wave Doppler techniques capable of recording arterial and Doppler measures for 
long periods continuously (Stout., 2009). 
 
Further to this, an acute rise of hyperglycaemia was found to be independently 
associated with a simultaneous decrease in endothelial function and an increase in 
oxidative stress and inflammatory biomarkers in young adults with type 1 diabetes 
(Ceriello et al., 2010). Interestingly in this study, the administration of vitamin C – 
even in the presence of hyperglycaemia – restored endothelial function, and reduced 
oxidative stress and inflammatory biomarkers.  
 
This finding was supported by another study, which demonstrated that ascorbic acid 
blocks the acute hyperglycaemic impairment of endothelial function in adolescents 
with type 1 diabetes (Hoffman, Dye & Bauer, 2012). It appears from these studies 
that hyperglycaemia induces an inflammatory response that is associated with 
oxidative stress, in a similar manner to that which occurs in acute severe injuries and 
sepsis. Stress hyperglycaemia may enhance the inflammatory response and hence 





The challenge with these studies is that they were mainly done in participants who 
had pre-existing chronic hyperglycaemic conditions, such as diabetes; and these 
individuals could have had other vascular pathologies, which could possibly have 
influenced these results (Ceriello et al., 2010). However, in some studies (Gordin et 
al., 2008), healthy individuals were also studied; hence the results obtained could 
also reflect what would happen if blood glucose levels were acutely elevated in 
critically ill patients with stress hyperglycaemia. 
 
Having discussed the adverse effects of stress hyperglycaemia in critical illness, and 
highlighted that these effects could be attenuated by vitamin C, it is important to note 
that there is an interesting relationship between vitamin C and glucose. The 
mechanisms of transport of each across the cell membrane are competitive, and this 
has clinical implications for patients with severe sepsis and hyperglycaemia, as 
described below. 
 
Vitamin C exists in endothelial cells mainly in the form of ascorbic acid (ascorbate), 
which is transported into the cell through a specific sodium-dependent vitamin C 
transporter 2 (SVCT2) (Seno et al., 2004). This is in contrast to the exterior of the 
cell where vitamin C mainly exists in its oxidised form, DHA. DHA is structurally 
similar to glucose. Rumsey et al. (1997) first illustrated that glucose transporter 
isoforms GLUT1 and GLUT3 also facilitate the transport of dehydroascorbic acid 
into the cell. After being transported into the cells, dehydroascorbic acid is quickly 
reduced to ascorbic acid (Wilson, 2009).  
 
Usually, the endothelial cells tend to retain ascorbic acid (Davis et al., 2006; Wilson, 
2005; Wu et al., 2007) so that the concentrations are higher than in the extracellular 
fluid; and it is only released to the extracellular fluid in a regulated fashion (Wilson, 
2009) using calcium-dependent mechanisms (Davis et al., 2006).  
 
In hyperglycaemic conditions, glucose competitively inhibits the uptake of 
dehydroascorbic acid by the endothelial cells; and so, hyperglycaemia may mimic 
vitamin C deficiency. In normal physiological conditions in healthy individuals, the 
expected glucose-to-vitamin C ratio has been estimated to be 88:1 (Price, Price & 




conditions. Furthermore, hyperglycaemia is known to increase the urinary loss of 
vitamin C (Will & Byers, 1996). Ascorbate deficiency mediated by acute 
hyperglycaemia in endothelial cells has been ascribed to the impairment of 
endothelium-dependent vasodilation in healthy human subjects – an effect which can 
be reversed by the acute administration of vitamin C (Price, Price & Reynolds, 2001; 
Wilson & Wu, 2012; Williams SB et al., 1998; Biesalski & McGregor 2007).  
 
Thus, the plasma-vitamin C to glucose ratio also seems important for adequate 
vitamin C bioactivity. Possibly an increase in the concentration of vitamin C would 
correct hyperglycaemia-induced inhibition of dehydroascorbic acid uptake by the 
endothelial cells, and improve vaso-responsiveness and restore normal endothelial 
function. Hyperglycaemia-induced vitamin C deficiency is exacerbated by decreased 
uptake and consumption of vitamin C, as a consequence of the inflammatory 
response as is described below. 
 
In a laboratory study using cultured human umbilical-vein endothelial cells, it was 
demonstrated that inflammatory molecules, such as TNF- α and IL-1ß, significantly 
suppressed the uptake of ascorbic acid through the SVCT2 in a dose- and time-
dependent manner (Seno et al., 2004). This implies that low vitamin C status in 
plasma and endothelial cells in septic shock with hyperglycaemia would result from 
the following mechanisms: Firstly, due to losses by oxidative stress where ROS may 
oxidize ascorbate to DHA, and then oxidize the latter irreversibly; and secondly, 
through the increased urinary excretion that occurs in hyperglycaemic states (Will & 
Byers, 1996). Thirdly, the inhibition of SVC2 transport of ascorbic acid by 
inflammatory molecules; and lastly, by the effect of competitive inhibition of 
dehydroascorbic acid transport by GLUT1 and GLUT3 in hyperglycaemic 
conditions, where the glucose-to-vitamin C ratio is significantly raised (Wilson, 
2009). 
 
It has further been illustrated in an in vitro study that ascorbate blocks the stimulation 
of ROS production through many pathways – including NADPH oxidase activity in 
microvascular endothelial cells (Wu et al., 2007). It is also well-known that vitamin 
C supplementation results in the mitigation of the inflammatory response in septic 




ability to reverse hyperglycaemia-induced endothelial dysfunction, would suggest 
that supplementation in septic shock might improve outcome.It would be of interest, 
therefore, to measure and investigate the ratio of glucose-to-vitamin C in septic 
shock, and its relationship to oxidative stress and markers of endothelial dysfunction. 
 
Apart from oxidative stress and hyperglycaemia, the microcirculation has recently 
been recognised as being of primary importance in septic shock, where the normal 
endothelial function is deranged (Kanoore et al., 2013; De Backer et al., 2013). 
 
1.5. Endothelial function 
 
1.5.1. Endothelial function under normal physiological conditions 
Before looking at the microcirculatory dysfunction associated with sepsis, it is 
important to briefly explain how the normal endothelium functions. 
 
Although only a simple monolayer, the healthy endothelium has been described as 
optimally placed and able to respond to physical and chemical signals by the 
production of a wide range of factors that regulate vascular tone, cellular adhesion, 
thromboresistance, smooth muscle cell proliferation, and vessel-wall inflammation 
(Deanfield, Halcox & Rabelink, 2007). Through the production and release of 
several vasoactive molecules that relax or constrict the vessel, and through its 
response to the circulating vasoactive mediators, such as bradykinin and thrombin, 
the endothelium is able to affect vascular tone (Deanfield, Halcox & Rabelink, 
2007). In effect, these functions have a direct role in the balance of tissue-oxygen 
supply and metabolic demand through the regulation of vessel tone; and they are 
involved in the remodelling of vascular structure and long-term organ perfusion 
(Stamler et al., 2003).  
 
In normal physiology, nitric oxide has been proven to be the main relaxant factor in 
blood vessels (Furchgott & Zawadzki, 1980). It is derived through the conversion of 
L-arginine to citrulline, by the action of the endothelial nitric oxide synthase system 
(eNOS), in the presence of co-factors such as tetrahydrobiopterin (BH4) 




oxide; and under normal physiological conditions, it is responsible for normal 
endothelial functions (Tyml, Li & Wilson, 2008).  
 
However, these normal processes are disrupted in severe sepsis. Endothelial 
dysfunction has been closely associated with the pathophysiology of the progression 
of sepsis to septic shock that results in multi-organ failure. Actually, the definition of 
septic shock in itself describes a derangement in the endothelium, where severe 
sepsis is complicated by acute circulatory failure, which is characterised by persistent 
arterial hypotension – despite adequate fluid resuscitation, or by tissue hypoperfusion 
– that is manifested by a raised lactate concentration, and which is unexplained by 
any other causes (Dellinger et al., 2008).  
 
1.5.2. Endothelial dysfunction in sepsis 
Endothelial dysfunction in sepsis is characterised by a disruption of the endothelial 
barrier properties (Seno, 2004; Wilson, 2009); as well as by decreased endothelial 
reactivity to vasoconstrictive and vasodilatory substances (De Backer et al., 2013). 
These are mediated by increased leukocyte and platelet aggregation, and an increase 
in inducible nitric oxide synthase (iNOS) expression, which is the pathological nitric 
oxide synthase pathway that can exert a negative feedback on the endothelial nitric 
oxide synthase expression (Boisramé-Helms et al., 2013). It has been established, 
through experimental models of sepsis, that septic insults to the endothelial cell, 
stimulate NADPH oxidase and iNOS activity via cytokines (Wu, Wilson & Tyml, 
2003; Li et al., 2005). Inducible nitric oxide synthase is also responsible for the 
generation of nitric oxide in amounts 1000-fold greater than constitutive amounts in 
basal endothelial function.  
 
The consequences of this progression include a severely disrupted ability of the 
vascular smooth muscle to respond appropriately to vasoconstrictors, resulting in the 
refractory shock, which often occurs in severe sepsis. Furthermore, NADPH oxidase 
elevates production of ROS by synthesizing superoxide inside endothelial cells, and 
setting off free-radical chain reactions (Li et al., 2005). These free radicals cause 
injury to the endothelium, and play a role in the impairment of capillary blood flow 




to become leaky to fluid and renders the maintenance of adequate blood pressure by 
the provision of intravenous (IV) fluid challenging. 
 
One of the other mechanisms associated with microcirculatory dysfunction in 
literature; is activation of coagulation. Using in vitro controlled experiment models, 
it was illustrated that normal neutrophils exposed to plasma from patients with septic 
shock demonstrated a significant increase in aggregation and endothelial cell 
adherence with associated decreases in neutrophil rolling velocity (Kirschenbaum et 
al., 2004). These changes were significantly enhanced in the presence of platelets and 
significantly attenuated in the presence of serum, which is fibrinogen depleted. 
Microvascular perfusion at the surface of these cell cultures was altered more with 
septic plasma than with septic serum, and especially in the presence of platelets.  
 
Another study of skeletal muscle microcirculation in septic wild male mice supported 
these findings and further demonstrated that  sepsis increases platelet aggregation, 
fibrin deposition, and the propensity for thrombosis in capillaries and that this 
process is P-selectin dependent (Secor et al., 2010). These data highlight the role of 
coagulation factors, leucocyte adhesion and platelets in microvascular alterations, 
even in the absence of overt thrombotic events.  
 
Marechal et al. (2008) in their experiments with septic rats found that, apart from the 
hyporeactivity of vessels to vasoactive agents, there were associated microvascular 
derangements. There was decreased capillary density and significant increases in 
non-perfused and intermittently-perfused capillaries in the small intestine muscularis 
layer of septic rats, compared with the controls. These changes were associated with 
degradation of the glycocalyx. The glycocalyx is the gel-like layer covering the 
endothelial surface; and there has been increased research on this area in recent years 
(Woodcock & Woodcock, 2012). The glycocalyx is very sensitive to oxidative stress 
and increased inflammatory mediators; and degradation of the glycocalyx is, 
therefore, prominent in sepsis (Marechal et al., 2008). It has also been demonstrated 
in other studies that LPS-elicited plasma hyluronan release and a reduction in 
endothelial surface thickness is indicative of glycocalyx degradation (Henry & 





A recent study in acutely ill patients by Ince’s group showed that patients with sepsis 
had increased degradation of the glycocalyx; and this was associated with 
microvascular blood flow derangements (Donati et al., 2013). Increased production 
of inflammatory mediators and ROS also influence oxidative stress-induced 
disruption of tight junctions by mechanisms such as protein modification such as 
thiol oxidation, phosphorylation, nitration and carbonylation (Rao, 2008). 
Heterogeneous capillary blood flow has been observed in different tissues, where 
tissue oxygenation was impaired; and multiple organ dysfunction and failure ensued 
(Ince, 2005).  
 
1.5.2.1. Soluble vascular cell adhesion molecule-1 (sVCAM-1) and E-selectin as 
biomarkers of endothelial dysfunction 
There are some biomarkers associated with endothelial dysfunction and damage in 
sepsis. These biomarkers are expressed when the endothelium is activated or 
damaged – not only during sepsis – but also during systemic inflammation of any 
cause, and by biochemical alterations, such as shear stress and hydrostatic pressure 
(Reinhart et al., 2002). Endothelial activation is mediated by cytokines (for example 
interleukin-1 (IL-1) and TNF-α), proteases, growth factors and vasoactive 
compounds (Hack & Zeerleder, 2001).  
 
The biomarkers of endothelial dysfunction include E-selectin, soluble vascular 
adhesion molecule 1 (sVCAM-1), platelet-derived growth factor (PDGF), endothelin 
(ET), and intercellular adhesion molecule-1 (ICAM-1) (Reinhart et al., 2002). E-
selectin and sVCAM-1 will be briefly discussed because of their relevance to this 
study. 
 
E-selectin is a glycoprotein that mediates rolling adhesion, the first step in leukocyte 
adhesion onto the endothelium (Reinhart et al., 2002). E-selectin is unique to the 
endothelium; and, in most vessels, de novo synthesis and expression can be induced 
within two hours and peaks at about six hours, in response to inflammatory stimuli or 
disturbed blood flow (Kansas, 1996; Sipkins et al., 2005). Studies have illustrated 
that E-selectin is an early marker for sepsis and the systemic inflammatory response, 
regardless of the cause, following stimulation by endotoxin and pro-inflammatory 




regulated in the endothelium in areas of chronic inflammation (Keelan et al., 1994; 
Picker et al., 1991). It is also clear that E-selectin is expressed in viable endothelial 
cells, mediates apoptosis, and that necrosis does not participate in its release 
(Harrington et al., 2006; Leeuwenberg et al., 1992; Pigott et al., 1992).  
 
E-selectin has been associated with angiogenesis (Koch et al., 1995); and its 
expression has been detected in the skin and parts of bone-marrow microvasculature 
(Sipkins et al., 2005). E-selectin has been shown to be involved in tumour growth 
and metastasis in bone tissue (Läubli & Borsig, 2010). This would possibly mean 
that the expression of E-selectin would be enhanced in both inflammation and repair 
of the micro-vasculature. In fact, a recent study has confirmed that E-selectin is a 
marker of endothelial proliferation (Smadja, Mulliken & Bischoff, 2012). However, 
concerning organ failure and the risk of mortality, there has been controversy 
concerning the relationship between plasma E-selectin concentration and these 
variables (Cummings et al., 1997; Shapiro et al., 2010). Soriano et al. (2005), in their 
study, found that all markers of cell activation and inflammation (which stimulate E-
selectin expression), were significantly higher among survivors than non-survivors of 
sepsis – with the exception of nitric oxide, which was lower.  
 
These data support the hypothesis that an early increase, not decrease in 
inflammatory response, can be associated with improved survival rate (Soriano et al., 
2005). Interestingly, these authors in this same study demonstrated that there was a 
negative correlation between the markers of inflammation and the SOFA score. This 
suggests that lower levels of plasma E-selectin could be expected with worsening 
organ failure. It is not surprising, therefore, that E-selectin has been found to be a 
less reliable marker of organ dysfunction and mortality than other endothelial 
markers, such as soluble VCAM-1 and soluble fms-like tyrosine kinase 1 (sFlt-1) 
(Skibsted et al., 2013). 
 
Soluble VCAM-1 participates in the adhesion of leukocytes to the endothelium at the 
site of inflammation (Paulus, Jennewein & Zacharowski, 2011). Unlike E-selectin, 
sVCAM-1 is expressed on leukocytes and a variety of other cell types, in addition to 
the endothelium (Reinhart et al., 2002). Soluble VCAM-1 has mechanical functions 




leukocytes (Paulus, Jennewein & Zacharowski, 2011). This molecule mediates 
leukocyte activation events that may lead to tissue damage by the release of 
lysosomal enzymes and the production of ROS (Reinhart et al., 2002). Increased 
plasma levels of sVCAM-1 would therefore be expected in both conditions of 
increased cellular damage and increased oxidative stress. A persistent increase in 
plasma sVCAM-1 was observed in septic patients with persistent multi-organ failure 
(Whalen et al., 2000).  
 
Endothelial dysfunction subsequently gives rise to the microcirculatory dysfunction 
that has been observed in both animal and human studies. 
 
1.5.3. Microcirculatory alterations, the mechanisms and consequences in sepsis 
It has been shown through many clinical studies by Can Ince’s group that 
microcirculatory dysfunction is the motor for sepsis-induced organ dysfunction and 
failure (Gomez et al., 2014; Ince, 2005; Piagnerelli, Ince & Dubin, 2012).  
 
Most studies in animal models of sepsis have reported deranged capillary perfusion 
in different organs. Farquhar et al. (1996) in a classical randomised controlled study 
reported decreased perfused capillary density of the small bowel in a normotensive 
rat caecal ligation and perforation (CLP) model of sepsis. Although limited by a 
small number of analysed animals (six) in each group, this study described deranged 
microcirculation that occurred despite maintenance of mean arterial pressure by 
intravenous fluid administration – a model that would explain organ hypo-perfusion 
in severely septic patients – even when blood pressure is within the normal range. 
Similar results were found by Ellis et al. (2002).  
 
In another study in male pigs – using a modified orthogonal polarization spectral 
device to study the microcirculation, it was shown that septic shock caused a 
markedly decreased functional microvascular density of the sublingual and gut 
regions (Verdant et al., 2009). The weakness of this study was that there was no use 
of vasopressors, as is the case in human septic shock. Furthermore, this study had an 
imbalance between the sham and intervention animals. It also had small sample sizes 
– of three and seven – in sham and septic animals, respectively, reducing the power 




response in sepsis between pigs and humans; and so this may not be directly 
translated to humans. Despite these limitations, the study had a key finding that the 
sublingual circulation, just like the bowel microcirculation, could be of use in the 
study of microcirculation in severe sepsis. This technique is now used in human 
microcirculation studies.  
 
A more recent study showed, for the first time, the possible mechanisms associated 
with microcirculatory dysfunction (Secor et al., 2010). This study utilised a fluid 
resuscitated model of polymicrobial sepsis in male wild type mice injected with 





), and gp91phox (a subunit of NADPH oxidase) knockout 
(gp91phox
-/-
). The results showed, for the first time, that sepsis increases platelet 
aggregation, fibrin deposition, and the propensity for thrombosis in capillaries – and 
that capillary flow stoppage requires platelets, P-selectin, and coagulation activation.  
 
The same authors further illustrated in this study that capillary platelet adhesion can 
be prevented or reversed by gp91phox and iNOS deficiencies, ascorbate, and local 
BH4. This study is important, since it describes the possible mechanisms associated 
with microvascular dysfunction in severe sepsis; and hence, it offers some insight 
into the exploration of treatment targets. Interestingly enough, the study suggests that 
the microvascular dysfunction could be prevented, and even reversed. It also 
suggests that platelet adhesion to the endothelium that leads to capillary blood flow 
impairment is enhanced by ROS, which promotes the P-selectin expression, and is 
dependent on NADPH oxidase.  
 
Have human clinical studies shown similar effects on the microcirculation in severe 
sepsis? It has been shown using an orthogonal polarization spectral imaging 
technique that, patients with severe sepsis have decreased functional microvascular 
density than healthy volunteers and non-septic critically ill patients (De Backer et al., 
2002). These results confirmed, and were supported by other human Doppler 
techniques (Hernandez, Bruhn & Ince, 2013; Edul et al., 2012; Sair et al., 2001) or 
plethysmography (Kirschenbaum et al., 2000; Sair et al., 2001; Neviere et al., 1996; 





Non-survivors of severe sepsis have been shown to have worse microvascular 
dysfunction than survivors (De Backer et al., 2002). This would infer that, factors 
that lead to microcirculatory dysfunction such as oxidative stress, activation of 
platelet plugging, and turning on of iNOS (Secor et al., 2010; Tyml, Li & Wilson, 
2008) are more pronounced in these patients. On the other hand, this could also mean 
that known factors that prevent or reverse these effects, such as vitamin C and BH4 
(Armour et al., 2001; Wilson, 2009; Wu, Wilson & Tyml, 2003; Tyml, Li & Wilson, 
2008a) are either inhibited or they are in lower concentrations in non-survivors than 
they are in survivors.  
 
None of the human studies on the microcirculation in septic shock presented here 
was a randomised control trial. Moreover, these studies did not concentrate on the 
mechanisms that could give insight into treatment options. Nevertheless, these 
studies confirm that human sepsis is associated with microcirculatory dysfunction, 
which leads to multi-organ dysfunction and failure. The evidence further suggests 
that the microcirculatory pathological changes are more pronounced in non-survivors 
than in survivors; and they are a strong predictor of outcome (De Backer et al., 
2013a; Trzeciak et al., 2007).  
 
There is hope, however; and it lies in the fact that the microcirculatory lesion 
associated with septic shock in humans is reversible. It has been shown that local 
application of acetylcholine was able to reverse the sepsis-induced microvascular 
blood flow alterations (De Backer et al., 2002), confirming previous findings in the 
experimental models of septic shock in animals (Secor et al., 2010; Wilson, 2009; 
Wu, Tyml & Wilson, 2002). 
 
With this evidence, the hypothesis that targeting the microcirculation, distinct from 
the macrocirculation, could potentially improve organ failure in sepsis (Trzeciak et 
al., 2008), and be the way forward in reducing the morbidity and the mortality 
associated with septic shock. It should be considered, however, that microcirculatory 
alterations are not the sole mechanism contributing to the organ dysfunction, because 
cellular metabolic alteration – including mitochondrial dysfunction – also contributes 





On the other hand, addressing the microcirculatory dysfunction could still be a step 
forward in addressing the morbidity, and possibly mortality, associated with septic 
shock. This could partly be achieved through addressing sepsis-induced oxidative 
stress – by supplementation with a substance known to promote normal endothelial 
dysfunction – and one which has the potential to prevent and reverse microvascular 
dysfunction, such as vitamin C. 
 
1.6. The role of vitamin C in severe sepsis 
Recently, there has been strong evidence forthcoming, suggesting that the 
supplementation of vitamin C in sepsis would be one of the potential therapeutic 
strategies in the management thereof (Wilson, 2013). The next section reviews the 
micronutrient vitamin C and the available evidence of its various roles in the 
treatment of sepsis.  
 
Ascorbate has been shown to influence survival in mouse models of sepsis. Gaut et 
al. (2006), showed that that ascorbate-deficient mice had an increased mortality 
following infection with Klebsiella pneumoniae, a gram-negative bacterium that also 
causes sepsis in humans (Heyland et al., 2013), compared to mice on vitamin C 
supplementation. Prior to this, Wu et al. (2004) found that an intravenous bolus of 
200mg/kg of ascorbate before introduction of infection through caecal ligation and 
puncture (CLP) in wild type mice dramatically increased the survival of the septic 
mice at 24 h post-CLP.  
 
This study also illustrated that an ascorbate bolus had beneficial systemic effects, 
including the prevention of oxidative stress, impaired pressor response to angiotensin 
II, and the maintenance of baseline arterial pressure. For the first time, this study 
group also showed that ascorbate inhibits the expression of iNOS mRNA induction 
in arterioles, the overproduction of nitrites/nitrates, and impaired arteriolar 
vasoconstriction response to angiotensin II. Ascorbate was also shown to have these 
benefits – even after a three-hour delay in these animals – a phenomenon that could 
be beneficial in the late phases of sepsis in humans. This study had the advantage 
that, even though it did not include antibiotic therapy, it included testing of the 
response of the arterioles to vasoconstrictors, following ascorbate infusion, a 




not incorporate intravenous fluid administration and antibiotics, as is usual in the 
treatment of human sepsis. 
 
Vitamin C has also been shown to inhibit and reverse the capillary blood flow 
impairment that occurs in sepsis, by inhibiting the NADPH oxidase activity, which 
plays a major role in this pathophysiology (Tyml, Li & Wilson, 2008). In addition, 
ascorbate was found to prevent or reverse sepsis-induced deficit in conducted 
arteriolar vasoconstriction and sepsis-induced increase in neuronal nitric oxide 
synthase (nNOS) enzymatic activity (Mckinnon, Lidington & Tyml, 2007).  
 
Another existing clinical challenge associated with severe sepsis is sepsis-induced 
lung injury. Fisher et al. (2011) conducted a laboratory study in wild type mice in 
which acute lung injury had been induced. It was discovered that mice without 
intervention demised within 28 hours of administration of LPS. On the other hand, in 
the intervention group that received vitamin C supplementation, up to 75% survived 
at 72 hours. Moreover, while there was some loss of capillary barrier function, 
exuberant pulmonary inflammation, and extensive microthrombus formation in the 
group without vitamin C supplementation, the group that received vitamin C 
supplementation had preserved lung architecture and barrier function, while showing 
attenuated pro-inflammatory chemokine expression and microvascular thrombosis.  
 
These results show that vitamin C, quite apart from having antioxidant properties, 
has other beneficial properties in the treatment of sepsis; hence, it has the potential to 
reduce morbidity and mortality if these properties were to be realised in human septic 
shock. Although animal data, whatever the species, cannot be applied directly to 
humans, these experiments do give us some understanding of the mechanisms of 
these effects, as also seen in humans (Berger, 2005). 
 
There have been few clinical studies in humans that have looked at vitamin C and 
critical illness. Long et al. (2003) found that only intravenous supplementation of at 
least 3000mg for at least 48 hours can restore the levels to normal. In another 
randomised controlled trial of post-operative patients, overnight intravenous 
administration of vitamin C, depending on the deficit, was shown to normalise the 




These two studies, however, did not report on the clinical impact of this 
replenishment.  
 
High dose vitamin C supplementation has been associated with improved clinical 
outcome in burns patients. Tanaka et al. (2000), in a randomised prospective study 
involving 37 patients with severe burns, supplemented high dose vitamin C at a dose 
of 66mg/kg in the first 24 hours of admission, and followed the patients for 7 days. 
Despite the small sample size of the study, it was shown that adjuvant high vitamin C 
supplementation reduced serum malondialdehyde levels, as markers of oxidative 
stress; and it reduced the amount of intravenous fluid required for resuscitation, 
reduced wound oedema; and it reduced the severity of respiratory dysfunction. This 
study is relevant because severely burnt patients exhibit characteristics similar to 
those of severe sepsis, where there is an increased level of oxidative stress and the 
presence of systemic inflammatory-response syndrome.  
 
Another randomised controlled trial, this time in critically ill surgical patients, 
showed that administration of α-tocopherol and ascorbic acid reduced the incidence 
of organ failure and shortened the ICU length of stay in this cohort (Nathens et al., 
2002). However, this study did not look at the clinical effects of pure vitamin C 
alone. A similar randomised controlled, double-blinded trial by Berger et al. (2008) 
showed that antioxidant supplementation, including 1.1g of vitamin C, significantly 
reduced the inflammatory response in cardiac surgery and trauma patients, a property 
that would surely be beneficial in severe sepsis.  
 
Vitamin C supplementation has also been associated with a decrease in organ 
dysfunction. Giladi et al. (2011), showed that supplementation with 1000mg vitamin 
C intravenously, 8 hourly, alongside α-tocopherol 1000 IU 8 hourly and selenium 
200 mcg daily for seven days, was associated with a reduction in respiratory failure, 
reduced ventilator-dependence, and a marked decrease in abdominal wall 
complications. It is not known, however, whether these results would be reproducible 






Septic shock is one of the most common disease processes in critical illness, and 
despite advances in its management over the years, it is associated with mortality of 
more than 30% in most settings (Kethireddy & Kumar, 2012; Labelle et al., 2012; 
Roman-Marchant et al., 2004). There is intense intravascular oxidative stress, which 
arises from the enormous production of free radicals in a non-regulated fashion, 
under conditions of inadequate antioxidative defenses (Macdonald, 2003; Galley et 
al., 1997; Doise et al., 2008). The requirement for vitamin C is, therefore, increased 
in critical illness, partly due to the need for replenishing antioxidant losses following 
irreversible biochemical reactions (Berger 2006). Not only is vitamin C found in low 
plasma concentrations; but it is also depleted in the endothelial cells in cases of 
severe sepsis (Wilson, 2009; Seno et al., 2004). 
 
The microcirculation has recently been recognised as the centre of several 
pathophysiological processes in septic shock (Kanoore et al., 2013), where normal 
endothelial function is deranged. It has recently been established that the endothelial 
dysfunction is mediated by the destruction of the glycocalyx, which is very sensitive 
to oxidative stress and high levels of inflammatory mediators (Donati et al., 2013). 
 
Another consideration is that the uncontrolled hyperglycaemia typical in sepsis and 
critical illness is one of the factors said to be responsible for the depletion of ascorbic 
acid in the endothelial cells, due to competitive inhibition of glucose on glucose 
transporters (Wilson 2009). Thus, the plasma vitamin C to glucose ratio seems 
important for adequate vitamin C bioactivity; but this has not been investigated well 
in cases of septic shock. 
 
Recently, there has been strong evidence suggesting that the supplementation of 
vitamin C in sepsis could be one of the potential therapeutic strategies in its 
management (Wilson, 2013). Vitamin C has the potential to replenish plasma vitamin 
C levels, to reduce oxidative stress, to prevent and reverse microcirculatory 
dysfunction, and to prevent, and even reverse, the adverse effects of hyperglycaemia, 
and also to reduce the morbidity and mortality associated with septic shock (De 
Backer et al., 2013a; Giladi et al., 2011; Nathens et al., 2002; Tanaka et al., 2000; 




Before exploring the effects of high dose vitamin C in septic shock in a South 
African setting, it is of value to put forward the following questions: 
In a population of critically ill patients with septic shock requiring inotropes,  
1. What is the plasma vitamin C status?  
2. What is the oxidative status of these patients?  
3. What are the levels of endothelial dysfunction markers in this patient group?  
4. What is the glucose-to-vitamin C ratio in this patient group?  
5. What are the associations of the above parameters with each other, the SOFA 
score, intravenous fluid requirements, and the inotrope requirement?  
 





CHAPTER 2: PROJECT AIM AND OBJECTIVES 
 
2.1. Aim 
To investigate the vitamin C status, the oxidative stress status, hyperglycaemia and 
endothelial function in critically ill patients with septic shock on inotropes.  
 
2.2. Specific objectives  
In a population of critically ill patients with septic shock requiring inotropes:  
 To measure the plasma vitamin C status;  
 To measure the plasma markers of oxidative stress; 
 To investigate hyperglycaemia and the plasma glucose-to-vitamin C ratio;  
 To measure the biomarkers of endothelial dysfunction;  
 Investigate the difference in the above parameters between survivors and 
non-survivors;  
 To investigate the associations of the above parameters with each other, 




H0 = Critically ill patients with septic shock have normal vitamin C status, no 
indication of oxidative stress, and no indication of endothelial dysfunction. 
 
HA = Critically ill patients with septic shock have low vitamin C status, high 














CHAPTER 3: MATERIALS AND METHODS 
 
3.1. Study design 
This is a prospective, cross-sectional study. 
 
3.2. Study population and location 
Participants included in the study were patients admitted to the multidisciplinary 
Intensive Care Units (ICU) at Groote Schuur Hospital, which is a tertiary-level 
facility, and an academic teaching hospital in Cape Town, South Africa. 
 
3.3. Inclusion and exclusion criteria 
 
3.3.1. Inclusion criteria 
 Adult patients (18 years and above)  
 Admitted to the multidisciplinary ICU with septic shock, requiring inotropic 
support expected to continue for at least 24 hours 
 
3.3.2. Exclusion criteria 
 BMI of less than 18kg/m2 
 Patients who – in the judgement of the intensivist – were not expected to 
survive more than 24 hours, despite maximal organ support 
 Patients who were on parenteral nutrition support at the time of screening for 
the study 
 Pregnant patients 
 Patients with gastrointestinal fistulas or other considerable exudative losses  
 Patients requiring renal dialysis at the time of study screening 
 Patients having had vitamin C supplementation of more than 100mg/day 









3.4. Sample-size calculation 
Using an alpha error of 5% and power of 80%, the sample size required to detect the 
prevalence of deficient vitamin C status, was calculated as follows: 
 
Since the expected prevalence of vitamin C deficiency in South African ICUs is not 
known, the study enrolled 25 patients – with the aim of detecting at least a 40% 
prevalence of vitamin C deficiency. 
 
3.5. Ethical considerations and approval 
 
3.5.1. Ethics and institutional approval 
The study was approved by the Human Research Ethics Committee of the Faculty of 
Health Sciences, University of Cape Town (Reference number UCT FHS HREC 
528/2011), and the medical superintendent for research of Groote Schuur Hospital. 
No subject was enrolled in the study until the protocol and subject information had 
been approved in writing by the Human Research Ethics Committee. 
 
3.5.2. Informed consent 
The study was performed in accordance with the principles of the Declaration of the 
Helsinki (2008), Good Clinical Practice (GCP) guidelines, and the laws of South 
Africa.  
 
Since the study population consisted of critically ill adults in ICU, the usual process 
of prior informed consent was not possible, because the patients were not competent 
to provide informed consent on their own behalf at the time of enrolment. The 
International Conference for Harmonisation (ICH), Good Clinical Practice (GCP) 
guidelines (4.8.15) states that: “In emergency situations, when prior consent of the 
subject is not possible, the consent of the subject's legally acceptable representative, 
if present, should be requested. When prior consent of the subject is not possible, and 
the subject’s legally acceptable representative is not available, enrolment of the 
subject should require measures described in the protocol and/or elsewhere, with 
documented approval/favourable opinion by the IRB/IEC, to protect the rights, safety 
Prevalence of deficiency 40% 60% 80% 




and wellbeing of the subject, and to ensure compliance with applicable regulatory 
requirements. The subject, or the subject's legally acceptable representative should be 
informed about the trial as soon as possible; and consent to continue and other 
consent as appropriate, should be requested.”  
 
The South African GCP guidelines (2.3.6.1) on research in critical care state that; 
“Characteristic features of intensive care research are the difficulties in 
communicating with patients receiving ventilator assistance, and the impairment of 
cognition in heavily sedated individuals. Whenever possible, information regarding 
intensive care research should be obtained from potential participants before their 
admission to that care”.  
 
Furthermore, regarding research involving unconscious patients, the South African 
GCP guidelines (2.3.6.5) state that: “The distinguishing feature of research with 
unconscious persons is that, because of their incapacity for cognition or 
communication, it is impossible for them to be informed about the research, or for a 
researcher to determine their wishes about it. Consent to participation in research by 
an unconscious person must be given by others, including relevant statutory 
authorities, on that person's behalf. Because of their extreme vulnerability, 
unconscious persons should be excluded from all but minimally invasive 
observational research. When research procedure precludes conformity to the 
principle of consent, and neither the prospective participant, nor the participant's 
representative, is able to give consent in advance, a research ethics committee may 
approve a research project without prior consent, if it is satisfied that: 
 Inclusion in the research project is not contrary to the interest of the patient; 
 The research is intended to be therapeutic, and the research intervention poses 
no more of a risk than that inherent in the patient's condition and alternative 
methods of treatment; 
 The research is based on valid scientific hypotheses, which support a 
reasonable possibility of benefit over standard care; and  
 As soon as reasonably possible, the participant and the participant’s relatives 
or legal representative will be informed of the participant’s inclusion in the 
research, and will be advised of their right to withdraw from the research, 




In the case of research proposals in which it is impractical to obtain consent before 
including in the research, a participant who is highly dependent on medical care, a 
research ethics committee must then be satisfied that: 
 Adequate provision will be made for informing patients and their relatives 
about the research, to ensure that stress and other emotional factors do not 
impair their understanding of it; and 
 The dependency of patients and their relatives on the medical personnel 
providing treatment does not affect any decision to participate”. 
 
Due to the observational nature of the study, and the minimal risk to study the 
participants, we were permitted to utilise a deferred informed consent procedure (see 
Appendix B1). Patients were enrolled in the study when they met the eligibility 
criteria. All blood samples and data collected were stored until the patient was well 
enough to give written informed consent for the use of such data. If the patient 
declined participation, all data and derived data were excluded from the study, and 
destroyed. In the case where a patient died before deferred written informed consent 
could be obtained, informed consent was waived; and we were permitted to utilize 
the data.  
 
The inclusion of patients who did not survive septic shock was important for the 
understanding of the factors associated with mortality in septic shock in the study.  
  
3.5.3. Confidentiality and anonymity 
To ensure the participant’s privacy and confidentiality, only authorised individuals 
working in the study had access to the individual information collected. The data 
from each individual patient were uniquely coded, so as not to identify the 
individual. The blood samples and the data generated in the study were also coded 
for analysis, in order to protect the patients’ identities.  
 
3.5.4. Participants’ rights and autonomy 
Participants had the right to withdraw, or to withdraw their data from the study, at 
any stage. The participants were protected by an insurance policy held by the 
University of Cape Town – in the unlikely event that they suffered a direct injury 




3.6. Participant recruitment 
Critically ill, septic patients in the ICU, or those being admitted to the ICU, were 
screened for study inclusion, as soon as they developed the need for inotropic 
support. The patients were recruited for the study within a 12-hour window from 
commencement of their treatment with inotropes. Those patients who satisfied the 
inclusion criteria were enrolled by a member of the research team. The patients were 
not re-enrolled for subsequent septic shock episodes, or for subsequent periods, 
where inotropes were required; but instead, they continued, according to the study 
assessment schedule.  
 
3.7. Data collection 
The data were collected from all the patients who were recruited, since they satisfied 
the inclusion criteria. A designated member of the study team collected the data from 
the participants. Clinical and demographic data were collected from the patients’ 
clinical records and from their charts during their admission. Blood sampling was 
done at baseline on enrolment – then daily – until inotrope cessation, and thereafter, 
at day seven, following the cessation of inotropic support. Laboratory analysis was 
done in the Redox laboratory of the Human Biology Department, Faculty of Health 
Sciences, at the University of Cape Town. 
 
3.7.1. Participant demographics 
Demographic data were recorded for all the participants of the study; and this 
included:  
 Age 
 Gender  
 Dates of hospital and intensive care (ICU) admission 
 Main diagnosis  
 Acute Physiology and Chronic Health Evaluation (APACHE) II score  
 
 
3.7.2. Anthropometric measures 
Following enrolment, the BMI of all the patients was estimated by a clinical 
dietician, according to the usual clinical practice. The recumbent length of the patient 




and with the bed in the flat position. The estimated body weight was then derived 
from the estimated BMI and actual recumbent length. 
 
3.7.3. Clinical data 
During their stay in ICU, patients were followed up daily commencing with the day 
of study inclusion (day 0) until ICU discharge or death (whichever came first); and 
during this time, the following clinical data were recorded from routine clinical 
charts and the medical records: 
 Daily lowest and highest mean arterial blood pressure  
 Daily mean blood glucose and ranges 
a) Inotrope requirement, which comprised: the number of days on inotropes;  
b) The total amount of inotropes used per day and per kg body mass; 
c) Inotrope-free days at day seven of the study period.  
 Daily fluid intake, output from all sources, and calculated fluid balance; 
 Calculated vitamin C intake from all enteral feeds and parenteral sources;  
 Daily Sequential Organ Failure Assessment (SOFA) score. The score is based on 
six different scores, one each for the: respiratory, cardiovascular, hepatic, 
coagulation, renal and neurological systems. Each organ score has a maximum 
worst score of 4, and a best score of 0. A final score is attained by adding the 


















Table 3.1: SOFA Score 
Organ System Score 
 0 1 2 3 4 
Respiratory: 
PaO2/FiO2 






















































15 13-14 10-20 6-9 <6 
 
For SOFA score: PO2 : FiO2 ratio convert PaO2 in kPa to mmHg by multiplying by 7.5 
Use FiO2 as decimal e.g. if PaO2 = 8kPa, Convert to mmHg = 8x 7.5 = 60mmHg if FiO2 = 0.4 
60 / 0.4 = 150 
a 
Adrenergic agents administered for at least one hour (doses given are in µg/kg per minute). FiO2, 
fractional inspired oxygen; MAP, Mean arterial pressure; PaO2, SOFA, Sequential Organ Failure 
Assessment 
(Doig et al., 2004). 
 
3.7.4. Clinical outcomes 
 Length of stay in ICU;  






3.8. Blood Sampling Procedures 
 
3.8.1. Method 
Blood sampling was done at baseline (day 0) of the study period within 12 hours 
from commencement of treatment with inotropes, then daily until inotrope cessation, 
and thereafter at day seven, following cessation of inotropic support.  
 
For each of these assays, a maximum of 5ml of whole blood was drawn into a 
heparinised/EDTA vacutainer, which was chilled and kept on ice. Once drawn, blood 
samples were gently rocked by hand to mix the blood with anticoagulant, and then 
placed on ice for transport to the laboratory. All samples were centrifuged at 
1000rpm for 10 minutes; and the plasma was drawn off into 1.5ml Eppendorf tubes, 
given a coded label, and stored at -20 to -80°C until batch analysis.  
 
The following laboratory assays were done: 
 TBARS as a marker of oxidative stress; 
 Plasma vitamin C Assay (Ferric Reducing Ascorbate Assay); 
 sVCAM-1 and E-selectin as markers of endothelial function. 
 
3.9. Laboratory analysis 
 
3.9.1. TBARS assay 
 
3.9.1.1. Principle 
This assay detects TBARS, which are products of lipid peroxidation, and are 
naturally present in biological specimens, such as plasma. Concentration levels of 
TBARS increase in response to oxidative stress (Armstrong & Browne, 1994). 
TBARS values are usually reported in malondaldehyde equivalents, a compound that 
results from the decomposition of polyunsaturated fatty acid lipid peroxides. 
 
The TBARS assay is a well-recognised, established method for quantifying lipid 
peroxides; and it is useful because of its sensitivity and simplicity (Liu et al., 1997). 
However, compared with new gas chromatography mass spectrometric assay 




towards compounds other than MDA (Yagi, K., 1998). The non-specificity probably 
results from the acid-heating step of the assay that causes the formation of artifactual 
TBA/MDA-like derivatives (Jentzsch et al., 1995; Liu et al., 1997).  
 
There are also other biomarkers of in vivo oxidative stress and lipid peroxidation, 
such as isoprostanes and isofurans – with higher sensitivity and specificity (Ware et 
al., 2011). However, the TBARS assay is more affordable and simpler to use.  It has 
been recommended, therefore, that the assay results be interpreted with an 
understanding of the limitations (Rael et al., 2004).  
 
The practical aspect of the assay involves the following steps: The samples and blank 
(distilled water) are first reacted with thiobarbituric acid (TBA) at 90°C. After the 45 
minute incubation, the blanks and samples are read fluorometrically at absorbance 
532 and 572 nm. The TBARS concentration in nmol/ml is then calculated by 
subtracting the blank absorbance value from the absorbance at 532 and 572 nm, 
respectively, and then calculating the arithmetic mean of the two readings. 
 
The final concentration was then calculated using the formula: 
 
Concentration in nmol/ml (μmol/L) = ([A532 – bl] – [A572 – bl] x [500/300]x[1000/200]) 
0.14 
Where: 
 A532 and A572 are the absorbance values at 532 and 572 wavelengths, 
respectively; 
 500 is the amount of butanol used in µl per sample;  
 bl are the values of the blanks; 
  300 is the final amount of sample read using a fluorometer; 
 1000 is the amount of microlitres equal to 1 millilitre; 
 200 is the amount of plasma in microlitres used from the original sample in 
the assay analysis; 






3.9.1.2. Assay reagents and method 
The TBARS assay was performed, according to a modified method devised by 
Jentzsch et al. (1996), and then developed and optimised at the Lipidology Research 
Laboratory, the University of Cape Town, as follows: 
 
Samples were thawed on ice. Distilled water was used as a blank to eliminate any 
background effect; and the assay was performed in duplicate. 
 
From the plasma samples, 200µl was pipetted into an Eppendorf tube, where 25µl of 
butylated hydroxytoluene (BHT) (Sigma-Aldrich Corporation St. Louis, MO, United 
States of America), 4mM in ethanol (Merck chemicals (Pty) Limited, Gauteng, 
Republic of South Africa), 200µl of 2M Ortho-phosphoric acid (Sigma-Aldrich 
Corporation St. Louis, MO, United States of America), and 25µl of TBA (2-
Thiobarbituric acid, Sigma-Aldrich Corporation St. Louis, MO, United States of 
America)  was added.  
 
The mixture was vortexed for 10 seconds, and then centrifuged at 13000rpm. 
Following the centrifugation, the mixture was heated for 45 minutes at 90
o
C to 
initiate chemical reactions. The mixture was put on ice for 2 minutes and brought to 
room temperature for 5 minutes. Then 500µl of n-butanol (Butan-1-ol, Merck 
chemicals (Pty) Limited, Gauteng, Republic of South Africa) and 50µl of saturated 
sodium chloride (Merck chemicals (Pty) Limited, Gauteng, Republic of South 
Africa) were added. The mixture was vortexed for 10 seconds and centrifuged for 2 
minutes at 12000rpm. Then, 300µl of the supernatant (pink-tinged) was pipetted into 
a 96 well plate and read at 532 and 572 nm, using a VersaMax plate reader 
(Molecular Devices Corporation, California 94089, USA).  
 
The TBARS concentration in nmol/ml was calculated, by subtracting the blank 
absorbance value from the absorbance at 532 and 572 nm, respectively, and 
calculating the arithmetic mean of the two. The final concentration was then 





3.9.2. Vitamin C assay (Ferric Reducing Ascorbate Assay) 
 
3.9.2.1. Principle 
The assay is based on the principle that Fe 
3+
 is reduced to Fe 
2+
 by any antioxidants 
present. The ferrous iron is chelated with a colorimetric probe to produce a product 
with a strong absorbance band, which is detected between 545 and 600 nm. Adding 
ascorbate oxidase to the parallel samples removes any ascorbate present, leaving a 




Vitamin C concentration in the plasma was determined using a Ferric Reducing 
Ascorbate (FRASC) assay kit (Catalog #K671-100) provided by BioVision Research 
Products (CA 94043 USA). 
 
A standard curve was prepared, using the standard provided with the kit; and 
dilutions were made using distilled water to generate 0, 2, 4, 6, 8 and 10 nmol per 
well of ascorbic acid.  
 
A volume of 100µl of each sample was then added to a paired set of wells in a 96-
well plate. One of the pairs represented a well for total antioxidant present, and the 
other a background well (ascorbate-depleted well). 10µl of distilled water was added 
to the total antioxidant well, while to the background well, 10µl of ascorbate oxidase 
was added. 
 
The plate was incubated for 15 minutes at room temperature to allow depletion of all 
the ascorbate. Ascorbic acid reaction mix was prepared, according to the kit protocol; 
and 100µl of this mix was added to the wells containing the ascorbic acid standard 
and the test samples. The assay was done in duplicate; and the reading was done 
within 2 to 3 minutes at 593 nm using a VersaMax plate reader (Molecular Devices 





Calculations were done by first subtracting the values of the background wells from 
the wells with total antioxidants present. The difference was optic density, due to 
ascorbic acid. 
 
Concentration (C) = Ascorbate concentration in the sample, was calculated from the 
following equation: 
 
C = (At – AB) / (slope of the standard curve)/V = nmol/ml = µM 
Where: 
 At = absorbance of the total antioxidant well; 
 Ab = absorbance of the background well with ascorbate oxidase; 
 Slope = absorbance at 10 nmol standard – 0 nmol standard / 10 nmol; 
 V = sample volume added to the reaction well (in ml). 
 
3.9.3. Enzyme-linked immunosorbent assay (ELISA) 
 
3.9.3.1. Principle 
ELISA is a powerful method for detecting and quantifying a specific protein in a 
complex mixture; and it was originally described by Engval and Perlmann (1971). 
This method enables analysis of protein samples immobilized in a micro-plate well, 
using specific antibodies.  
 
The human ELISAs are in vitro enzyme-linked immunosorbent assays for the 
quantitative measurement of specific proteins in plasma and other biological fluids. 
These assays employ antibodies specific to the proteins of interest. Standards and 
samples are pipetted into the wells; and the protein present in the samples is bound to 
the wells by the immobilized antibodies. The wells are then washed and biotinylated 
antibody is added. Washing is done again, in order to remove unbound biotinylated 
antibody; and then HRP-conjugated streptavidin is pipetted to the wells. The wells 
are again washed and tetramethylbenzidine (TMB) is added to the wells, after which 
a blue colour develops. The colour change shows that the secondary antibody has 
bound to the primary antibody, which strongly implies an immune reaction to the test 




bound. Stop solution is then added and the colour changes from blue to yellow, and 
the intensity of the colour is read at a specific wavelength. 
 
3.9.3.2. Method  
ELISA for soluble vascular cell adhesion molecule (sVCAM-1): 
The ELISA for sVCAM-1 was performed using a commercial human sVCAM-1 
ELISA kit (RayBiotech Company, GA 30092, USA).  
 
The samples were thawed on ice; and then all the reagents were brought to room 
temperature. Standard solutions were made, according to protocol, to produce 
60ng/ml, 20ng/ml, 6.667ng/ml, 2.222ng/ml, 0.74ng/ml. 0.247ng/ml and 0 ng/ml 
(animal serum with 0.09% sodium chloride). The samples were diluted 50-fold. 
100µl of each standard and sample was added to the wells in duplicate. The wells 
were then incubated overnight at 4
o 
C, with gentle shaking using a shaker. 
 
The following day, the solution was discarded; and washing was done, using a wash 
buffer solution provided with the kit. The washing was done 7 times rather than 4 
times, according to the guidelines with 5 minutes for each wash. Washing 7 times 
was preferred, because this was found to be the optimal number of washes that 
prevented sample components or antibodies cross-reacting with the blocking buffer, 
resulting in a high background signal. Expert opinion was sought when optimizing 
the assay from an experienced academic staff member from the Division of 
Haematology at the University of Cape Town.  
 
After the wash, 100µl of prepared biotinylated antibody was then added to each well; 
and the wells were incubated for 1.5 hours to allow binding. This was done at room 
temperature, with gentle shaking, using a shaker. 
 
The washing step was repeated, as previously done, after discarding the solution. 
100µl of streptavidin solution was then added to each well; and the wells were 
incubated at room temperature, with gentle shaking for 45 minutes. The solutions 
were then discarded and the washing step was repeated, but this time only 4 time, 




particular specific proteins and were expected to have less unwanted proteins, if any, 
compared to the sample plasma. 
 
TMB one-step substrate reagent (100µl) was added to each well; and the wells were 
incubated in the dark for 30 min. Then 50µl of stop solution was added; and the 
reading was done at 450 nm, using a VersaMax plate reader (Molecular Devices 
Corporation, California 94089, USA). 
 
Calculations to determine the actual concentration of sVCAM-1 were done by 
plotting a curve of the standards, and using the slope to calculate the different 
unknown values for the samples. 
 
ELISA for E-selectin: 
The ELISA for E-selectin was performed, using the Human E-selectin ELISA kit 
(RayBiotech Company, GA USA).  
 
The samples were thawed on ice; and then all the reagents were brought to room 
temperature. Standard solutions were then prepared, according to the kit protocol, to 
produce 18000pg/ml, 6000pg/ml, 2000pg/ml, 666.7pg/ml, 222.2pg/ml. 74.07pg/ml 
24.69 and blank provided with the kit (animal serum with 0.09% sodium chloride). 
The samples were diluted 100-fold to produce the expected concentration to be 
detected, and to fall within the kit’s detectable range, considering the expected high 
levels in the sample of septic patients, as in the previous literature. 
 
100µl of each standard and sample was added to the wells in duplicate. The wells 




The following day, the solution was discarded; and washing was done, using a wash 
buffer solution provided with the kit. The washing was done 7 times, rather than 4 
times, according to the guidelines, with 5-minute time intervals for each wash. 
Washing 7 times was preferred, because this was found to be the optimal number of 
washes that prevented sample components or antibodies cross-reacting with the 





After the wash, 100µl of prepared biotinylated antibody was then added to each well; 
and the wells were incubated for 1.5 hours to allow binding. This was done at room 
temperature, with gentle shaking using a shaker. 
 
The washing step was repeated, as previously done, after discarding the solution. 
100µl of streptavidin solution was then added to each well; and the wells were 
incubated at room temperature, with gentle shaking for 45 minutes. The solutions 
were then discarded; and the washing step was repeated, but this time, only 4 times, 
according to the kit protocol, because the solutions being washed had particular 
specific proteins; and they were expected to have less unwanted proteins, if any, 
compared to the sample plasma. 
 
TMB one-step substrate reagent (100µl) was then added to each well; and the wells 
were incubated in the dark for 30 minutes. Then 50µl of stop solution was added; and 
the reading was done at 450 nm, using a VersaMax plate reader (Molecular Devices 
Corporation, California 94089, USA). 
 
Calculations to find the equivalent concentrations of E-selectin were done by plotting 
a curve of the standards, and using the slope to calculate the different unknown 
values for the samples. 
 
3.10. Statistical analysis 
Statistical analysis of the data was done using STATA12 and STATISTICA 11 
(Statsoft, USA). The Shapiro-Wilks normality test was used to test the data for 
normality. Summary statistics were used to provide a general description of the study 
population by age, sex and the source of infection. Descriptive statistics were 
expressed as means ± SD and medians (IQR) for the continuous data, depending on 
whether the data were parametric or non-parametric. The plasma Vitamin C levels, 
TBARS, glucose-to-vitamin C ratio, sVCAM-1 and E-selectin levels were reported 
as medians (IQR) because they were non-parametric.  
 
The Wilcoxon rank-sum test test (the Mann-Whitney test) was used to test the null 
hypothesis – that the two populations had equal medians in terms of investigating 




septic shock, both males and females. Testing the differences between the means and 
the medians of the measured variables at different points in time, i.e. the baseline, 
day 1, and day 7, the Wilcoxon rank-sum test and the repeated measures for ANOVA 
or the Friedman (K-related samples) were used.  
To measure the associations between the different variables; vitamin C, TBARS, 
sVCAM-1, E-selectin and clinical outcomes of interest, the Spearman’s test of 








CHAPTER 4: RESULTS 
 
4.1. Participants 
Recruitment for the study was done in the period between March 2012 and 
December 2012. The recruitment of the participants was done by one of the 
designated research team members on call, on a rotational basis – actively searching 
for potential participants. Referral of potential participants was also done by the ICU 
staff. During the study period, a total of 80 patients were screened for possible 
inclusion in the study. Of these, 25 patients could be included. Table 4.1 summarises 
the participant’s demographic data and their baseline characteristics. 
 
Table 4.1: Participant demographics (n = 25) 
Source of Sepsis 
Intra-abdominal 8/25 (32%) 
Respiratory 7/25 (28%) 
Necrotizing Fasciitis 4/25 (16%) 
Polytrauma with secondary 
infection 
3/25 (12%) 
Soft Tissue 3/25 (12%) 
Gender (males / females) 7/18 (28% males, 72% females) 
Mean age (years) 49 ± 15.6 
Mean BMI (kg/m
2
) 28.2 ± 6.4 
Mean APACHE II Score 20.1 ± 10.5 
Mean baseline SOFA Score 10.6 ± 2.8 
Mean lowest Mean Arterial Pressure (mmHg) 54.9 ± 10.9 
Survived / Died 16 (64%) / 9 (36%) 
Median length of ICU stay (days) 6 ( 4-10) 
APACHE II: Acute Physiology and Chronic Health Evaluation 
SOFA Score: Sequential Organ Failure Assessment Score 
BMI: Body Mass Index 
 
Those study participants who had surgical diagnoses represented 80% (n=20) of the 
study group; while 16% (n=4) had internal medical diagnoses; and 4% (n=1) had a 
gynaecological diagnosis. The mean APACHE score of the participants was 20.1 ± 
10.5, with no statistical difference between surgical 17.9 ±11.1 and medical patients 
24.125 ±10.6. The baseline SOFA is consistent with patients suffering septic shock – 




score between the survivors and the non-survivors, it was found that the baseline 
SOFA score was lower in survivors 9.75 ± 2.7 compared to non-survivors of septic 
shock 12.2 ± 2.1; and this difference was statistically significant, using a two-sample 
t-test (p=0.014). This indicates that the non-survivors were more severely ill than the 
survivors at baseline. 
 
The mortality rate in the patients of this study was 36% and this is comparable to the 
mortality rate associated with septic shock worldwide of 20%-51% (Kethireddy & 
Kumar, 2012; Labelle et al., 2012). The median length of ICU stay was six days (4-
10) with no significant difference between the survivors and the non-survivors of 
septic shock (p = 0.6).  
 
4.2. Screen failures 
From the 80 patients who were screened, 55 patients were excluded from the study. 
Figure 4.1 indicates the reasons for their exclusion. Most of the patients were not 
included into the study because they were not timeously referred. However, a 
considerable proportion was also excluded, because they were either on dialysis, or 
receiving parenteral nutrition. 
 
 
Figure 4.1: Screen failures 
BMI less than 18Kg/m2 (n=5)
Not expected to survive more than
24 hours (n=1)
On total parenteral nutrition ( n=9)
On dialysis (n=9)
On vitamin C supplementation (n=3)






4.3. Plasma vitamin C levels 
The first objective of the study was to measure the plasma vitamin C status in the 
patient group. Plasma samples drawn at baseline, on day one and on day seven, and 
were analysed for vitamin C, using the ferric reducing ascorbate assay. Figure 4.2 
shows the box plots of the plasma-vitamin C levels at the different times of the study 
period.  
 
For the duration of the study, the median (IQR) vitamin C levels were low in the 
participants with no significant change [baseline (5.65 nmol/ml [2.31 – 8.02]), on 
day one 5.9 nmol/ml (3.73 – 14.15), and on day seven 5.61 nmol/ml (3.69 – 9.35) (p 
= 0.83). One patient at baseline and another at day one of the study period had 
undetectable levels of vitamin C in their plasma. Only three of the participants had 
vitamin C levels within the normal reference range of 11 – 114 nmol/ml at baseline.  
At day one, five patients; and at day seven, three patients had levels within the 
normal reference range.  
 
 
Grey band represents the normal reference range (11-114nmol/ml) 
 °= outliers, * = extremes 
Figure 4.2: Vitamin C levels over the study period 
Normal plasma vitamin C reference range 11-114 nmol/ml 




The Wilcoxon rank-sum test was used to test the difference in the vitamin C levels 
between the males and the females. There was no significant difference in the 
vitamin C plasma levels between males and females at any of the time points (p = 0.8 
at baseline; p = 0.3 at day one; and p = 0.3 at day seven), respectively. Similarly, no 
significant differences were found in the baseline plasma vitamin C concentrations in 
survivors and non-survivors of septic shock (p = 0.9). 
 
Figure 4.3 depicts the trend of vitamin C daily intake over the study period in A 
(females) and B (males). Of note is that the mean vitamin C intake from all the 
sources in female patients fell below the recommended daily allowance (RDA), 
within the first 48 hours (75mg/day) following diagnosis of septic shock; and the 
readings were only above the RDA on days: two, four, five and six. Males had 
oscillating vitamin C intake, and had intake levels below the RDA on all the study 
days except days one, three and six.  
 




































































Recommended daily allowance (RDA) for healthy males: 90mg/day 
B. (Males) 
Figure 4.3. Daily mean vitamin C intake (mg) in ICU over the study period in A 
(females) and B (males) 
 
4.4. Plasma TBARS as a marker of oxidative stress 
The second objective of the study was to measure the plasma concentration of 
TBARS as a marker of oxidative stress. TBARS assay was analysed at the same time 
points of the study as the vitamin C above (baseline, day one and day seven).  
 
Table 4.2 shows the median TBARS levels at the indicated time periods of the study. 
At baseline, the median TBARS levels were more than four times higher than the 
upper reference range values. The TBARS levels continued to be high at day one, 










Table 4.2: Median (IQR) plasma TBARS (nmol/ml) over the study period 




 Baseline (n=25) Day 1 (n=19) Day 7 (n=15)  
Median (IQR) 
TBARS (nmol/ml) 
19.5 (14-37) 20.4 (13-64) 13.3 (9-18) 0.52 
Reference range 1.86-3.91 nmol/ml (Miller et al., 2012) 
 
However, as depicted in Figure 4.4, non-survivors of septic shock had higher median 
TBARS levels at baseline (43.8 nmol/ml [23.6 – 47.7]) than did the survivors (16.9 
nmol/ml [11.9 – 21.7]), (p = 0.008).  
 




























l) P  0.008
°= outliers 
Figure 4.4. Oxidative stress levels (measured as TBARS) in survivors and non-
survivors of ICU 
 
This indicates that the non-survivors of septic shock had more than double the levels 
of oxidative stress than did the survivors. Despite this, even the survivors still had a 
n=16                    n=9 




median TBARS concentration of approximately four times higher than the upper 
limit of the reference range. 
 
4.5. Plasma glucose 
Daily blood glucose measurements were done, as part of the routine care in ICU. At 
baseline, day one and day seven, blood glucose measurements were done specially 
for the calculation of blood glucose-to-vitamin C ratio – for the study purposes. 
 
Table 4.3 shows the median (IQR) daily highest, lowest and mean blood glucose 
records for the designated days. The table shows that the mean blood glucose was 
well-controlled in the ICU over the study period, when compared to the Groote 
Schuur ICU protocol target range (5 – 8 mmol/l). The mean blood glucose was above 
the ICU target range at baseline, but significantly reduced to the ICU target values at 
day one and day seven, respectively. There was, however, no statistically significant 
change in either the median highest blood glucose (p = 0.2), or the median lowest 
blood glucose (p = 0.8) level over the study period. No difference was shown in the 
baseline mean blood glucose between survivors 9.4 mmol/l (7.5 – 10.5) and non-
survivors 7.7mmol/l (6.5 – 8.8) (p = 0.22). 
 
Table 4.3: Median (IQR) blood glucose measurements (mmol/l) over the study 
period 
 
Groote Schuur Hospital ICU blood glucose target range (5-8 mmol/l) 
  




change over study 
period 
 Baseline Day 1 Day 7  
Highest reading 12 (9.3-14.3) 10.3 (8.45-11.7) 8 (7.25-10) 0.2 
Lowest reading 5.5 (4.6-6.4) 5.25 (3.85-6.25) 5.75 (4.7-6.1) 0.8 




4.6. Plasma glucose to vitamin C ratio 
The subsequent step was to determine the glucose-to-vitamin C ratio in the study 
group. Figure 4.5 depicts the median (IQR) of the ratios over the study days. It 
should be noted that there was a high median (IQR) ratio of glucose-to-vitamin C at 
baseline (1756 (998 – 3539)), with no significant change at the other time points (day 
one [1178 (727 – 1877)] and day seven (1043 [593 – 2000]). 
 
Normal plasma glucose to vitamin C expected ratio = 88 (Price and Reynolds, 2001) 
°= outliers, * = extremes 
Figure 4.5: Glucose to vitamin C ratio over the study period 
 
4.7. Association between plasma glucose and vitamin C  
The next objective of the study was to investigate the relationship between plasma 
glucose and vitamin C. There was no correlation between glucose and vitamin C 
status at any of the time points [baseline (r = -0.06, p = 0.8), day one (r = -0.2, p = 
0.5), and day seven (r = 0.06, p = 0.9)]. Further analysis, as illustrated in Figure 4.6, 
showed that there was no significant correlation between the baseline vitamin C and 
the maximum blood glucose in the survivors (Fig 4.6A), (r = 0.13, p = 0.63).  
In the non-survivors, however (Fig 4.6B), there was a significant negative correlation 
(r = -0.7, p = 0.04). 
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B. (ICU non-survivors) 
Figure 4.6. Correlation between baseline vitamin C status and maximum blood 
glucose in A (ICU survivors) and B (ICU non-survivors) 
n = 16 (r = 0.13; p = 0.63) 




4.8. Biomarkers of endothelial function 
The fourth objective of the study was to measure the circulating markers of 
endothelial function. Plasma soluble VCAM-1 and E-selectin were measured using 
commercial ELISA kits. 
 
Normal reference range 72 – 349 ng/ml (Whalen et al., 2000)  
Figure 4.7. Plasma sVCAM-1 concentrations over the study period 
 
As illustrated in Figure 4.7, the median (IQR) plasma sVCAM-1-1 levels were raised 
at baseline (1219 ng/ml [603 – 2319]) but decreased significantly at day one (657 
ng/ml (177 – 2149) and day seven (105 ng/ml (67 – 135) when tested with 
Friedman’s ANOVA (p = 0.001) against day 0).  
 
Figure 4.8 compares the baseline sVCAM-1 levels between the survivors and the 
non-survivors. It was noted that there was a significant difference in the baseline 
sVCAM-1 levels, which were higher in non-survivors (2212 ng/ml (1370 – 4081) 
than in the survivors of septic shock (767 ng/ml (357 – 1764), (p = 0.01).  
n=25            n=19      n=15 





 Normal reference range 72 – 349 ng/ml (Whalen et al., 2000) 
Figure 4.8. Baseline sVCAM-1 levels between survivors and non-survivors 
 
Figure 4.9 shows the plasma E-selectin levels in the patients. There was a significant 
increase in the median levels from day one to day seven (p = 0.003). Figure 4.10 
displays a comparison of E-selectin levels between the survivors and the non-
survivors at baseline. The E-selectin levels were significantly higher in survivors 
13.1ng/ml (7.8 – 24.1) than they were in non-survivors 7.1ng/ml (6.2 – 15.3) at 
baseline (p = 0.04). 
n=16                  n=9 




Normal reference range for E-selectin 0.93 – 2.8ng/ml (Newman et al., 1993) 
°= outliers, * = extremes 
Figure 4.9: Plasma E-selectin concentrations over the study days 
 
 
n=25              n=19           n=15 





Normal reference range for E-selectin 0.93 – 2.8ng/ml (Newman et al., 1993) 
Figure 4.10. Comparison of plasma E-selectin levels between survivors and non-
survivors at baseline 
 
There was no correlation between the plasma sVCAM-1 and E-selectin at any of the 
time points of the study; baseline (r = -0.3, p = 0.15), day 1 (r = 0.07, p=0.8), and day 
7 (r = 0.7, p = 0.09). 
 
4.9. Correlation between vitamin C and TBARS 
The other objective of the study was to investigate the relationship between vitamin 
C and TBARS, as a marker of oxidative stress. There was no significant correlation 
between vitamin C and TBARS levels at baseline (r = 0.15, p = 0.47) or day one (r = 
0.16, p = 0.51). At day seven, however, there was a negative correlation approaching 









4.10. Association between endothelial function markers and TBARS as a 
marker of oxidative stress 
We also investigated the correlation between E-selectin and sVCAM-1, respectively, 
as markers of endothelial dysfunction, and TBARS as a marker of oxidative stress. 
 
Table 4.4: Association between endothelial function markers and TBARS as a 
marker of oxidative stress 
Study day sVCAM-1 vs. TBARS E-selectin vs. TBARS 
 Spearman’s rho p-value Spearman’s rho p-value 
Baseline 0.45 0.02 0.08 0.7 
Day 1 0.57 0.01 0.16 0.5 
Day 7 0.6 0.01 -0.08 0.78 
 
As portrayed in Table 4.4 above, there was a significant positive correlation between 
sVCAM-1and TBARS at all the time points of the study – thereby indicating that 
increased sVCAM-1 levels were associated with higher levels of oxidative stress. 
There was, however, no significant correlation observed between E-selectin and 
TBARS at any of the time points; and the associations were very weak. 
 
4.11. Association between endothelial function markers and vitamin C status 
We also investigated the correlation between sVCAM-1, as well E-selectin and 
vitamin C status. No correlation was found between sVCAM-1 and vitamin C status 
at baseline (r = -0.02, p = 0.09), day one (r = -0.18, p = 0.4), or day seven (r = 0.16, p 
= 0.58). Similar results were found when the correlation between E-selectin and 
vitamin C was tested at baseline (r = 0.08, p = 0.69), day one (r = 0.16, p = 0.7), and 
at day seven (r = -0.08, p = 0.78). 
 
4.12. Association between biomarkers and clinical markers 
4.12.1. Association between baseline TBARS, sVCAM-1 and SOFA Score 
Figure 4.11 shows the association between baseline TBARS (left y-axis), sVCAM-1 
(right y-axis) and Sequential Organ Failure Assessment score (x-axis). Increased 
TBARS levels were associated with high SOFA scores (r = 0.47, p = 0.02). 
Interestingly, baseline high sVCAM-1 levels were also associated with high SOFA 


























































Figure 4.11: Correlation between baseline TBARS and SOFA score, baseline 
sVCAM-1 and SOFA score 
 
4.12.2. Association between baseline TBARS and intravenous fluid requirement 
and Inotrope-free days 
Figure 4.12 portrays the association between baseline TBARS (x-axis), as a marker 
of oxidative stress and inotrope-free days at day seven (left y-axis), and the 
intravenous fluid requirements (right y-axis). There was a negative association 
between Inotrope-free days at day seven and TBARS (r = -0.44, p <0.015) in the 
total group. Baseline IV fluid volume was positively associated with TBARS in non-
survivors (r = 0.75, p = 0.02).  
 
This illustrates that patients with increased oxidative stress required more days on 
inotropic support, and had increased baseline intravenous fluid requirements. 
 
 
r = 0.57, p = 0.003  



























































 Inotrope free days
 IV fluid requirements
Figure 4.12: Correlation between baseline TBARS and Inotrope-free days at 
day 7, and baseline TBARS and baseline intravenous fluid requirements 
 
4.13. Summary of results 
This study has shown that septic shock is associated with low levels of plasma 
vitamin C, which persisted until day seven after the cessation of inotropic support. 
There was also evidence of oxidative stress in the patients, marked by increased 
levels of TBARS; and there was no significant reduction in these levels at day seven 
of the study. Non-survivors in this study had increased levels of oxidative stress and 
organ failure compared to the survivors.  
 
The results of this study have also shown that the plasma glucose-to-vitamin C ratios 
were higher than the normal expected ratio at all of the study days. As regards 
plasma biomarkers of endothelial dysfunction, both markers (sVCAM-1 and E-
selectin) were high at baseline. However, sVCAM-1 levels were significantly higher 
in non-survivors than in survivors; but this difference was not observed in the E-
selectin levels. Furthermore, the sVCAM-1 levels fell significantly at day one, and 
normalized at day seven; while the E-selectin levels were constantly raised at day 
one, as at baseline, and further increased significantly at day seven.  
  r = 0.75, p = 0.02  




No association was found between the biomarkers of endothelial dysfunction and 
those of vitamin C levels. Both sVCAM-1 and TBARS associated positively to 
SOFA score; and increased TBARS levels were associated with increased 
requirements for intravenous fluids for resuscitation, and an increased number of 
days on inotropes. 
 
Table 4.5 summarises the major differences in the study variables between survivors 
and non-survivors. 
 
Table 4.5: Summary table of baseline characteristic differences between 






















(vitamin C vs 
maximum  
glucose) 
Survivors 9.8 ± 2.7 5.9 (2.2-8.4) 16.9  
(11.9-21.7) 
767  
(357 – 1764) 
13.1  
(7.8 – 24.1) 
 r = 0.13  
 p = 0.63 
Non-survivors 12.2 ± 2.1 4.3 (3.2-6.7) 43.8  
(23.6-47.7) 
2212  
(1370 – 4081 
7.1  
(6.2 – 15.3) 
 r = -0.7  
 p = 0.04 
 
















CHAPTER 5: DISCUSSION 
This is the first study in a South African setting to investigate vitamin C status, 
oxidative stress levels, hyperglycaemia, and their association with endothelial 
dysfunction in patients with septic shock. In summary, the results present a picture of 
critically ill patients with a profound vitamin C deficit in the context of extreme 
oxidative stress – both of which persisted after the resolution of the acute period of 
septic shock. Furthermore, the findings indicate that these responses differ between 
survivors and non-survivors. The non-survivors appeared to have a more exaggerated 
response.  
 
Increased oxidative stress and endothelial damage in the patients were associated 
with increased organ dysfunction, as marked by the SOFA score. We also 
demonstrated higher plasma glucose-to-vitamin C ratio in these patients, indicating 
hyperglycaemia, low vitamin C, or the occurrence of both. It was found that 
oxidative stress correlated with the biomarkers of endothelial damage, and with 
clinically relevant indicators of the extent of shock, i.e. the duration of inotropic 
support and intravenous fluid requirement.  
 
These results will be discussed further in the remainder of this chapter, and the 
relevance for the clinical care of patients with septic shock will be suggested. 
 
5.1.  Study participants 
The sample population in this study was representative of a well-defined group of 
critically ill patients with septic shock, and acutely deranged physiology. At baseline, 
prior to study entry, all the study participants met the SIRS criteria and the specified 
criteria for septic shock, the definition of which is persistent sepsis-induced 
hypotension – despite adequate fluid resuscitation (Dellinger et al., 2013). 
 
The lowest mean arterial blood pressure for these patients was 54.9 ± 10.9 mmHg 
and they all required inotropic support due to septic shock at baseline. The baseline 
SOFA score was 10.6 ± 2.8. This SOFA score is consistent with the expected degree 
of multi-organ dysfunction and/or failure known to occur with septic shock 




Evaluation (APACHE) II score was 20.1 ± 10.5, indicating that the patients were 
systemically stressed.  
 
The mortality rate for septic shock in our study of 36% is within the global range of 
mortality of 20%-51% for this diagnosis (Kethireddy & Kumar, 2012; Labelle et al., 
2012). The non-survivors had a significantly higher baseline mean SOFA score than 
did the survivors, which is consistent with the known prognostic significance of the 
SOFA score (Bale et al., 2013; Jones, Trzeciak & Kline, 2009).  
 
5.2. Vitamin C status 
The vast majority (88%) of these patients had low baseline vitamin C levels. The 
median vitamin C levels were 5.65nmol/ml, which is only 51% of the lower limit of 
reference range (11nmol/l), below which manifestations of clinical vitamin C 
deficiency syndromes could be expected if the status remained at this level 
chronically.  
 
The cause of these very low plasma vitamin C levels in our study could be as a result 
of three major factors. The first of these factors is critical illness. It has been 
established that critical illness is associated with oxidative stress, in which there is 
increased utilisation of antioxidant micronutrients, including vitamin C (Doise et al., 
2008; Heyland et al., 2013; Long et al., 2003). The oxidative stress, and hence the 
antioxidant utilisation, is further increased in patients with SIRS, such as in septic 
shock (Alonso de Vega et al., 2002). The patients from the current study were 
critically ill, with a severe form of SIRS-exhibiting condition and increased markers 
of oxidative stress. It could be expected, therefore, that there would be an accelerated 
oxidation of ascorbate at a rate that exceeds reduction – due to increased oxidative 
stress (Galley, Davies & Webster, 1996; Galley et al., 1997; Spada et al., 2008). 
Damaged proteins, due to trauma or sepsis-associated oxidative stress, and 
extracellular ferritin, may be sources of redox-reactive iron that also oxidizes 
ascorbate in blood and interstitial fluid (Deubzer et al., 2010; Du, Cullen & Buettner, 
2012).  
 
Vitamin C losses from plasma are also due to the redistribution of blood volume 




therewith (Wilson, 2013). Losses can also occur through dialysis, since vitamin C is 
water soluble (Coveney et al., 2011; Raimann et al., 2013), but this is not applicable 
to this study, since the patients on dialysis were excluded to remove this confounding 
factor. 
 
Thirdly, very low baseline vitamin C levels in this study could be due to low plasma 
vitamin C prior to the onset of septic shock. There is a lack of recent South African 
data on the vitamin C status in healthy people. Segal et al. (1995) demonstrated that 
there was a significant difference in the median vitamin C levels between healthy 
controls from Manchester, United Kingdom (74 nmol/ml) and Johannesburg, South 
Africa (14 nmol/ml) (p < 0.001), respectively. Low dietary intake of micronutrients, 
including vitamin C, has been reported in most parts of South Africa (Linster & Van 
Schaftingen, 2007; MacIntyre et al., 2002). At least some of the South African 
population may, therefore, be predisposed to low vitamin C levels in acute illness – 
due to a pre-existing nutritional compromise in the diet. Septic shock then further 
worsens the already suboptimal plasma vitamin C levels – due to the increased 
demands associated with the disease condition (Berger, 2006). 
 
In addition to the above factors, low vitamin C levels were persistent, possibly due to 
inability to restore the normal plasma levels nutritionally while in ICU. The nutrition 
(from all sources) delivered to the patients of this study had a mean upper range of 
120 mg of vitamin C at all the time points of the study, and did not replenish the 
vitamin C plasma levels. However, it should be kept in mind that patients who were 
on TPN during screening were not included in the study.  
 
In a review of vitamin C requirements in critically ill patients, Berger (2009) 
commented that only parenteral vitamin C administration of not less than 3g/day for 
three days would be adequate to bring the plasma vitamin C up to normal. This 
recommendation was based on the data from acute surgical patients.  
  
The vitamin C levels in our study did not resolve at day seven, following the episode 
of septic shock. This finding confirms another published study, where the vitamin C 
levels in patients with severe sepsis were only restored to normal range (11 – 114 




2008). These results mean that the low vitamin C status associated with severe sepsis 
persists for at least a week, unless a targeted intervention towards normalising the 
levels is offered. 
 
These results have some clinical relevance. The question lies in the extent to which 
this acute, very low vitamin C status could have on clinical outcome. It is known that 
vitamin C is a potent water-soluble antioxidant, and that it is involved in normal 
vascular function (Halliwell, 1997b; Wilson, 2009). It is difficult, given our study 
design, to ascertain exactly what the influence of vitamin C levels as low as we have 
demonstrated, might be on the clinical outcome of the patients.  
 
It has been demonstrated in previous animal and human studies that supplementation 
with high doses of vitamin C, and replenishing the levels in critical illness and septic 
shock improved the outcome (Gaut et al., 2006; Tanaka et al., 2000; Tyml, Li & 
Wilson, 2008). It is plausible that maintaining the vitamin C levels at normal and 
even above, is an important factor that has the potential to improve the patients’ 
outcome. Considering this, the persistence of deficient levels of vitamin C in our 
study population is of concern – but it is not unexpected – as supplementation with 
high doses of vitamin C was not included in the current study. 
 
5.3. The extent and effects of oxidative stress in septic shock 
Since vitamin C plays a central role as an antioxidant, it was important to measure 
the oxidative stress in the patients. The results of this study showed that there was 
increased oxidative stress at baseline in the study participants, as marked by 
increased plasma TBARS 19.5nmol/ml (14 – 37) (reference range = 1.86 – 
3.91nmol/ml).  
 
The oxidative stress was evident in all the study participants. Literature has 
previously shown that critical illness, regardless of cause, is associated with 
oxidative stress (MacDonald, 2003; Galley et al., 1997; Doise et al., 2008). This is 
especially true in illnesses, such as septic shock, that exhibit a systemic inflammatory 
response syndrome (Alonso de Vega et al., 2002 Berger, 2005a; Berger, 2006; 





The extremely low vitamin C levels in the patients of the current study have already 
been discussed; and this could have influenced the antioxidant capacity of the 
patients, as supported by the negative correlation obtained on day 7 between the 
vitamin C plasma levels and TBARS. It should also be considered that besides being 
an antioxidant, vitamin C has other associated functions, such as collagen synthesis 
and endothelial function, which may be at high demand in the early stages of septic 
shock; and, as such, the levels might not only be explained by the presence or 
absence of oxidative stress at this stage.  
 
Furthermore, there are other antioxidants (which were not measured in our study) 
known to be associated with a reduction of oxidative stress – including vitamin E and 
beta-carotene, glutathione, albumin, and superoxide dismutase. Changes in the levels 
of these molecules could possibly mask the association between vitamin C and 
oxidative stress – especially when vitamin C is only present in low concentrations 
(Berger, 2005; Lovat & Preiser, 2003).  
 
Hyperglycaemia, which is also common and secondary to stress in critical illness, is 
another contributing factor to oxidative stress (Ceriello et al., 2008; Dungan, 
Braithwaite & Preiser, 2009). High plasma glucose promotes oxidative stress through 
the induction of an inflammatory response (Ceriello et al., 2008; Gordin et al., 2008). 
Patients in this present study had higher plasma glucose levels than the ICU target 
range at baseline; and this could in part explain the increased oxidative stress.  
 
Considering that increased oxidative stress, if not controlled, causes damage to DNA, 
RNA, proteins, carbohydrates and unsaturated fatty acids of the cell membranes 
(Berger, 2005b; Goodyear-Bruch & Pierce, 2002), the patients in this study were at 
increased risk of cellular and tissue damage. In fact, the increased plasma TBARS at 
baseline in this study is evidence of lipid peroxidation, a process which, once 
initiated, may become self-propagating unless terminated, causing cell and tissue 
injury (Podloucká et al., 2013).  
 
Interestingly, the TBARS levels at baseline were positively associated with the 
baseline SOFA score, indicating increased organ dysfunction and/or failure. Thus, 




confirms other previous similar findings, where reduced levels of antioxidants and 
increased levels of MDA, as well as conjugated trienes were useful as markers of 
oxidative stress (Biesalski & McGregor, 2007; Heyland et al., 2013; 
Nepomniashchikh et al., 2009). 
 
Linked to this finding, is the finding that TBARS positively correlates with sVCAM-
1, a marker of endothelial damage, which was also high at the baseline. Previous 
literature has shown that oxidative stress causes damage to the glycocalyx of the 
endothelial cell (Marechal et al., 2008). Endothelial dysfunction in sepsis has been 
demonstrated to cause microvascular dysfunction, the motor for sepsis-induced organ 
dysfunction and failure (Gomez et al., 2014; Piagnerelli, Ince & Dubin, 2012).  
 
Logically, it could be hypothesized that the increased oxidative stress in the patients 
of the current study influenced the increased incidence of organ dysfunction. On the 
other hand, the association between oxidative stress and the SOFA score could be a 
mere reflection of the association between severe SIRS that is associated with septic 
shock – with resulting organ failure and oxidative stress (REN, 2008). The results 
from a study by Huet et al. (2007) demonstrated that plasma from septic shock 
patients induced ROS formation by naive human umbilical vein endothelial cells 
(HUVEC); and the extent of ROS formation correlated with mortality and with the 
SOFA score. 
 
The current study points in the direction of a similar conclusion. The baseline 
oxidative stress marker was significantly higher in the non-survivors than in the 
survivors in this current study. This demonstrates that even though oxidative damage 
was evident in the whole group, non-survivors had significantly higher oxidative 
stress than survivors. However, it was also shown in this study that the non-survivors 
had increased organ dysfunction, when compared with that of the survivors. These 
results, therefore, demonstrate that increased oxidative stress is a marker of increased 
risk of death in this study; and this finding supports the previous similar findings of 






The results of this study also show that oxidative stress persisted at all the time points 
of the study period (day one TBARS 20.4 nmol/ml (13 – 64); day seven TBARS 13.3 
nmol/ml (9 – 18)) with no significant change (p = 0.52). Oxidative stress was 
therefore evident – even a week after the resolution of septic shock. This indicates 
that the patients in this study were still at risk of the consequences of increased 
oxidative stress – even after septic shock. It follows, therefore, that early 
management of oxidative stress in these patients could possibly have saved them 
from the risk of consequences of oxidative stress, which persists even after septic 
shock.  
 
Our findings are comparable to those of another study, which reported that patients 
with septic shock in Chile had persistently increased TBARS – even at day seven of 
follow up, and were only resolved by three months (Andresen et al., 2008). Careful 
consideration however should be given when managing oxidative stress in 
populations at risk, as it is not as simple as merely supplementing with dietary 
antioxidants. 
 
5.4. Hyperglycaemia and plasma glucose-to-vitamin C ratio 
It is understood that septic shock also induces stress hyperglycaemia, which may 
influence oxidative stress, and also reduce the uptake of vitamin C by endothelial 
cells – due to the competitive inhibition in sodium transporters (Ceriello et al., 2010; 
Dungan, Braithwaite & Preiser, 2009). Hyperglycaemia in septic shock could also 
result from the use of steroids in the management of septic shock, which is a 
common clinical practice (Fong & Cheung, 2013).  
 
In this study, the median blood glucose for the participants at baseline was 8.84 
mmol/l (7.3 – 10.1), which was above the upper limit of the ICU target range (5 – 8 
mmol/l). Considering that vitamin C has antioxidant and endothelial functions, 
hyperglycaemia-induced low vitamin C levels at the endothelial cellular level could 
influence both the endothelial dysfunction and the oxidative stress. At baseline, the 
maximum blood glucose in non-survivors had a negative correlation to plasma 






A previous study reported that high maximum blood glucose levels during the stay in 
ICU correlated with increased morbidity and mortality (Christiansen et al., 2004). It 
follows then, that the control of hyperglycaemia is an essential component in the 
management of these patients. 
 
In this current study, the median plasma glucose-to-vitamin C ratios at baseline 
(1756 [998 – 3539]), day one (1178 [727 – 1877]), and at day seven (1043 [593 – 
2000]) were above the expected value of 88, calculated from the ratio of the 
physiological levels of both glucose and vitamin C. The increased ratio could be 
explained by hyperglycaemia, low plasma vitamin C levels, or by the occurrence of 
both. In this study, there was hyperglycaemia at baseline, which was controlled at 
day one and day seven. Vitamin C levels, on the other hand, were persistently low at 
all of the time points of the study. The hyperglycaemia at baseline and the low levels 
of vitamin C are the likely explanations for the high plasma glucose-to-vitamin C 
ratios, persisting up to day seven, following the episode of septic shock. 
 
For the first time, this present study reports increased plasma glucose-to-vitamin C 
ratios in this patient group. This ratio is important because of its potential influence 
on endothelial function (since it influences the uptake of vitamin C),  and because 
hyperglycaemia itself is associated with endothelial dysfunction (Chen et al., 2011; 
Hoffman, Dye & Bauer, 2012; Quagliaro et al., 2005; Su et al., 2013). However, we 
did not find any correlation between the glucose-to-vitamin C ratio and endothelial 
dysfunction in this study. This could possibly be due to the fact that in septic shock, 
profound oxidative stress is what contributes more to endothelial damage, as 
confirmed by our results (TBARS positively correlated to sVCAM-1), than the 
influence of this ratio. It is this endothelial dysfunction that is now known to 
engineer the organ dysfunction associated with septic shock (Donati et al., 2013; 
Gomez et al., 2014). The next section therefore discusses the findings on endothelial 








5.5. Plasma biomarkers of endothelial dysfunction 
Evidence from previous studies has shown that oxidative stress causes damage to the 
endothelium (Sun et al., 2013). We have also discussed in previous sections that 
vitamin C status and hyperglycaemia may influence endothelial dysfunction 
(Hoffman, Dye & Bauer, 2012; Zhou et al., 2012). The objective to measure the 
markers of endothelial dysfunction was therefore important.  
 
5.5.1. Choice of markers of endothelial dysfunction  
We used soluble vascular cell adhesion molecule 1 (sVCAM-1) and E –selectin as 
biomarkers of endothelial dysfunction. Our choice of these biomarkers was based on 
the fact that both E-selectin and sVCAM-1 are highly expressed during sepsis (Cook-
Mills, Marchese & Abdala-Valencia, 2011; Skibsted et al., 2013). However, E-
selectin is specific to the endothelium; and it therefore increases in its expression to 
reflect endothelial activation (Sipkins et al., 2005). It is highly expressed in viable 
endothelial cells during acute inflammation and increased endothelial proliferation 
(Kräling et al., 1996; Smadja, Mulliken & Bischoff, 2012). 
 
On the other hand, sVCAM-1 is found in other cells and tissues, in addition to the 
endothelium (Reinhart et al., 2002). In the endothelium, sVCAM-1 has 
immunological, mechanical and intercellular transduction functions (Paulus, 
Jennewein & Zacharowski, 2011). Soluble VCAM-1 mediates leukocyte activation 
and morphological changes of endothelial cells; and this allows the infiltration of 
white cells through the endothelium; and it also mediates tissue damage, by release 
of lysosomal enzymes and the production of reactive oxygen species (Reinhart et al., 
2002). Endothelial and tissue damage are hence associated with increased levels of 
sVCAM-1; and such, it is seen in organ dysfunction and organ failure (Skibsted et 
al., 2013). 
 
5.5.2. Endothelial dysfunction associated with septic shock 
 In this study, both sVCAM and E-selectin were high at the baseline. Since it is 
known that increased inflammatory mediators and endotoxins, which are high in 
severe sepsis, induce the increased expression of these biomarkers, our results can be 
understood in this way (Reinhart et al., 2002). The published literature has also 




and E-selectin (Chen et al., 2011; Cook-Mills, Marchese & Abdala-Valencia, 2011); 
and we have already demonstrated hyperglycaemia in our study group.  
 
At baseline in this study, the sVCAM-1 levels were significantly higher in the non-
survivors than in the survivors (p = 0.01). This finding could be explained by 
considering the factors that influence the increased expression of this molecule. 
Firstly, it is known that sVCAM-1 mediates changes in the morphology of the 
endothelial cells – to allow for the infiltration of white blood cells into the 
extravascular space (Hortelano et al., 2010).  
 
In this way, sVCAM-1 promotes a further inflammatory response, which worsens the 
patient’s response to the infection, and predisposes the patient to microcirculatory 
dysfunction that leads to organ dysfunction and eventual organ failure. The results of 
this present study have shown that increased oxidative stress is associated with 
increased sVCAM-1 levels, and sVCAM-1 correlates positively with organ 
dysfunction. The non-survivors in this study also had increased oxidative stress; and 
this could be the other explanation for the increase in sVCAM-1 levels in this 
subgroup of patients. Thus, in this subset of our patients, sVCAM-1 reflected overall 
worse endothelial dysfunction, illness severity and an increased risk of mortality. 
 
In other studies, increased microbial stimulation has been associated with increased 
sVCAM-1 expression (Smeding et al., 2012). Considering that the non-survivors had 
an increased SOFA score and were sicker, it could be hypothesized that they had 
either had intense infection with an increased microbial load; or they had had a more 
pronounced inflammatory response, causing increased sVCAM-1 that influenced the 
severity of their illness – and then caused their death.  
 
In this study, baseline sVCAM-1 was associated with baseline TBARS (r = 0.45; p = 
0.02); and this association has been discussed in a previous section, on the extent and 
effects of oxidative stress in septic shock. Contrary to the sVCAM-1, there was no 
significant correlation found between E-selectin and TBARS. The hypothesis was 
that a positive correlation between these variables would be found. The lack of 




endothelial cells, a factor known to negatively affect the E-selectin expression 
(Harrington et al., 2006).  
 
This explanation would also explain our findings that E-selectin levels were higher in 
the survivors than in the non-survivors of our study. The non-survivors of septic 
shock in our study had increased levels of oxidative stress, with increased levels of 
sVCAM-1, marking endothelial damage. Since endothelial cell damage and necrosis 
do not induce E-selectin expression (Harrington et al., 2006; Leeuwenberg et al., 
1992; Pigott et al., 1992), it is not unexpected to find E-selectin levels higher in the 
survivors, who were expected to have relatively less endothelial damage than the 
non-survivors. 
 
The sVCAM-1 levels decreased at day one, and fell within a normal range at day 
seven, following the cessation of inotropic support for the patients who survived. 
This demonstrates that there was less cellular damage; and it also indicates recovery 
in endothelial functions, as septic shock was resolved. This was an expected result. 
On the other hand, the plasma E-selectin levels remained relatively stable from 
baseline to day one, but increased significantly at day seven (p = 0.003).  
 
This can be explained by the fact that, apart from the stimulation by inflammatory 
mediators, increased E-selectin expression has been described as a marker of 
proliferating endothelium; and it is known to be involved in angiogenesis (Kräling et 
al., 1996; Läubli & Borsig, 2010; Smadja, Mulliken & Bischoff, 2012). The 
increased E-selectin expression at day seven, following septic shock, may therefore 
reflect increased endothelial proliferation in repair and regeneration, following the 
episode of sepsis.  
 
The absence of any correlation between sVCAM-1 and E-selectin at any of the time 
points of this study could be as a result of a difference in the independent factors that 
affect the expression of the two biomarkers individually (Cook-Mills, Marchese & 
Abdala-Valencia, 2011; Cummings et al., 1997; Smadja, Mulliken & Bischoff, 
2012). This implies that even though both E-selectin and sVCAM-1 may be 
increased during inflammation, the expression of these biomarkers could display 




damage or proliferation that influence their expression (Eikemo, Sellevold & Videm, 
2004).  
 
However, yet another study showed significant correlation between sVCAM-1 and 
E-selectin. The reason for the difference in their result from our own is that their 
study was in patients with early sepsis; while our study included patients with septic 
shock, a more severe disease condition associated with organ dysfunction and failure.  
 
5.6. Association between biomarkers and clinical markers 
Considering the clinical implications of the vitamin C status and the levels of the 
biomarkers of oxidative stress and endothelial dysfunction investigated in this study, 
it was pertinent to investigate the correlation of these biomarkers with clinical 
markers. We demonstrated in the results of this study that both sVCAM-1 (as a 
marker of endothelial damage) and TBARS (as a marker of oxidative stress) were 
positively associated with the SOFA score. The increased sVCAM-1 levels in our 
study, therefore, marked increased organ failure; while the positive correlation 
between TBARS and SOFA score supports the hypothesis that septic shock 
predisposes an individual to overwhelming oxidative stress (Macdonald, Galley & 
Webster, 2003), both of which induce endothelial damage (De Backer et al., 2013). 
 
We did not find any correlation between vitamin C, at any point of the study, with 
the SOFA score. We expected a negative relationship. This relationship was perhaps 
not shown, due to the extreme low plasma levels of this micronutrient in the majority 
of the patients, which would hardly show any clinical effect. Otherwise, this study 
finding is difficult to explain. 
 
For the first time, to our knowledge, this study has demonstrated that increased 
oxidative stress at baseline is associated with an increased requirement for 
intravenous fluids for resuscitation in a septic shock patient collective. We have 
shown that oxidative stress is associated with endothelial damage marked by 
increased sVCAM-1 levels at baseline, and that the endothelial dysfunction is 
associated with increased organ dysfunction. One of the major organs affected in 




hypotension and microcirculatory dysfunction (Dellinger et al., 2013; Hernandez, 
Bruhn & Ince, 2013).  
 
Such patients require large amounts of intravenous fluids for resuscitation and 
inotropic support, to bring the blood pressure to physiologically acceptable levels 
(Dellinger et al., 2013). It could be deduced from this relationship that the level of 
oxidative stress determined the extent of endothelial damage and cardiovascular 
dysfunction, hence the amount of intravenous fluid required for resuscitation. 
However, due to the nature of our study design, we could not establish a cause-and-
effect relationship between the oxidative stress and intravenous fluid requirement for 
resuscitation.  
 
It could be hypothesized that reducing oxidative stress might result in the reduction 
of intravenous fluid requirements in such a patient group. Tanaka et al. (2000) in a 
randomized study showed that high doses of vitamin C supplementation in burn 
patients resulted in reduced oxidative stress levels and lower requirements of 
intravenous fluids for resuscitation in the patients in the supplementation group. 
Even though septic shock and burns are different disease conditions, they have 
common factors, since they both exhibit a profound inflammatory response 
syndrome, and are associated with increased oxidative stress. One could, therefore, 
infer that the effect of high doses of vitamin C on the reduction of oxidative stress 
and the reduction of the requirements of intravenous fluids could also be effective in 
septic shock patients.  
 
Another unique finding of this study is that increased oxidative stress was associated 
with more days on inotropic support. This demonstrates that increased oxidative 
stress in septic shock somehow influences circulatory dysfunction, so that this patient 
group requires more time on inotropes, presumably due to lingering endothelial 
dysfunction. Inotrope use is clinically very important, because it reflects illness 
severity, and therefore the need for organ support and ICU resources.  
 
Getting a patient off inotropes quickly is an indication of an accelerated 
improvement and response to the other critical aspects of sepsis control, such as 




patients with low oxidative stress in our study had a shorter duration on inotropic 
support, they were associated with accelerated improvement and response to 
treatment. Plausibly, management tailored towards addressing increased oxidative 
stress and its associated pathophysiology could yield a good response in these 
patients, and hence, a reduction of the duration on inotropes. 
 
5.7.  Limitations 
The results of this study must be interpreted in the context of its design as a cross- 
sectional study. In this regard, it can only report associations of variables; but it 
cannot demonstrate any cause-and-effect relationship. However, the design suits 
what the study aimed at – to investigate the vitamin C status, oxidative stress, 
hyperglycaemia, and endothelial function, in critically ill patients with septic shock, 
without intervening in any way.  
 
Our sample size was 25 patients, and although a relatively small sample, we met the 
sample size required for the planned statistical analysis. 
 
In this current study, the ferric reducing ascorbate assay for measuring the vitamin C 
levels in the plasma of the patients was used. High-performance liquid 
chromatography (HPLC) is currently the gold standard for measuring this 
micronutrient in plasma. However, the ferric reducing ascorbate assay offers a 
speedy and reliable alternative for screening plasma ascorbic acid, and it is 
frequently used in clinical research (Choy, Benzie & Cho, 2003; Chung et al., 2001). 
Furthermore, this method is relatively cheap and easy to use. Consequently, the use 
of this method was suitable and cost-effective in the current study.  
 
TBARS was used as a biomarker for assessing oxidative stress. There are other 
biomarkers of in vivo oxidative stress and lipid peroxidation, such as isoprostanes 
and isofurans (Ware et al., 2011) with higher sensitivity and specificity. 
Nevertheless, TBARS assay is an assay that has been highly optimised by 
experienced researchers in our research unit laboratory facility, where this analysis 
was done; and we therefore defend its use as justified in our setting.  
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It is recommended in many studies that more than one biomarker assessing the 
oxidative status be used; and in this current study, this could also pose a limitation. 
To investigate endothelial dysfunction, we used circulating (sVCAM-1 and E-
selectin, respectively); and we did not have any measures of vascular physiology, 
such as orthogonal polarization spectral imaging technique or biopsy that could give 
a picture of the in situ processes analysis (Fortin et al., 2010; Mathru & Lang, 2005). 
Due to the design of the study, in vivo assessment procedures were not indicated to 
assess the endothelium; and the use of circulating biomarkers was considered a 
suitable proxy for the observational purposes of this baseline study. 
5.8. Future directions 
Following the results of this observational study, many questions are still to be 
answered; and further research is definitely indicated. It is a concern that although 
guidelines exist for the management of septic shock, which are periodically 
reviewed, the mortality rate of septic shock is still high (Dellinger et al., 2013; 
Labelle et al., 2012); and this calls for further exploration and the incorporation of 
other management strategies.  
The low vitamin C levels in this patient group definitely require attention. The 
intervention should also target oxidative stress, which marks increased endothelial 
damage, the severity of illness, and the risk of death. Antioxidant supplementation 
would be one of the ways to combat the oxidative stress associated with septic shock. 
In a meta-analysis of studies that supplemented antioxidant micronutrients in 
critically ill patients, it has been shown that antioxidant supplementation is 
associated with a significant reduction in overall mortality among patients with 
higher risk of death (Manzanares et al., 2012). In a recent, randomised trial of mixed 
antioxidant micronutrients and glutamine, there was no benefit related to an outcome 
associated with antioxidant supplementation (Heyland et al., 2013). However, this 
trial supplemented vitamin C enterally and not parenterally, as some of the studies in 
the review did (Manzanares et al., 2012). In addition to this, this trial did not study 
the impact of vitamin C alone. Thus, this area still calls for further exploration and 
research. 
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Considering the results of the present study and other previous studies, the role of 
high-dose vitamin C supplementation warrants exploration, but with caution. Septic 
shock in our study was associated with the depletion of plasma vitamin C, a 
phenomenon shared with other settings, where the general population has normal 
levels of vitamin C. Intravenous vitamin C would be a cost-effective way to 
replenish plasma vitamin C levels in this patient group, because it is highly 
bioavailable, compared with enteral delivery (Wilson & Wu, 2012).  
It has been demonstrated in other patient groups of critical illness and animal models 
of septic shock that high-dosage vitamin C restored the vitamin C levels to normal 
(Gaut et al., 2006; Tanaka et al., 2000; Tyml, Li & Wilson, 2008). These studies 
further illustrated that high-dose supplementation with vitamin C reduced the 
oxidative stress, and promoted normal endothelial function. High-dose vitamin C in 
patients with septic shock could, consequently, be potentially effective in correcting 
the plasma glucose-to-vitamin C ratio, which was high in our study, by reducing the 
competitive inhibitive effect on endothelial cell transport by high blood glucose.  
In this way, vitamin C could also ameliorate the endothelial dysfunction caused by 
low vitamin C status. Ultimately, such an adjunctive intervention has the potential to 
reduce organ dysfunction, as well as the mortality associated with septic shock. 
If the potential effects of high-dose vitamin C could be realised, there would then be 
a potential to reduce the increased requirement for inotropes and intravenous fluids, 
as discussed in our study. Currently, the use of colloids has been discouraged, due to 
some poor outcomes associated with their use (Myburgh & McIntyre, 2013; Perel, 
Roberts & Ker, 2013).  
However, this implies that larger volumes of intravenous fluids would be required in 
the resuscitation of patients with septic shock, since crystalloids are not better 
volume expanders; and the use of large volumes may cause peripheral and 
pulmonary oedema (De Backer & Cortés, 2012; Jacob et al., 2012). In addition to 
this, a reduction in the number of days on inotropic support should reduce the 
exposure of these patients to the side-effects and complications associated with the 
prolonged use of vasopressor therapy, such as hypoperfusion (particularly affecting 
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the extremities, mesentery or kidneys), dysrhythmias, myocardial ischemia, 
peripheral extravasation with skin necrosis, and hyperglycaemia (Backer et al., 2003; 
Communal et al., 1998; Singh et al., 2001). This could also perhaps promote quicker 
recovery, and reduce the cost of such management in this patient group. 
Supplementation of vitamin C in patients with septic shock in a South African health 
setting would be even more justifiable, considering that the general population is at 
high risk of having low plasma vitamin C levels, when they become critically ill – 
due to the inadequate dietary intake of vitamin C. Our results showed very low 
vitamin C status at baseline, which persisted – even after the episode of septic shock. 
Thus, supplementation ought to be prompt, so that it prevents or reverses early 
microcirculatory dysfunction and its consequences; and it should be done in parallel 
with monitoring the oxidative stress status of the patient. 
It is with such a rationale that the next phase of this research project will embark on 
assessing the effects of high-dose vitamin C supplementation on the SOFA score, 
inotrope requirements, vitamin C status, oxidative stress, hyperglycaemia and the 
biomarkers of endothelial function in critically ill patients with septic shock. 
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APPENDIX A: Materials, Solutions and Equipment 
A1. Materials 
96 well sterile plate (Greiner Bio-one,Germany) 
Cellstar R cryovials (Greiner Bio-one,Germany) 
Disposable Pasteur pipettes (Laboratory and Scientific Equipment Company, SA) 
Disposable sterile 2ml syringe (Becton Dickinsonn, UK) 
Disposable sterile 5ml syringe (Becton Dickinsonn, UK) 
DNAse-, RNAse- free 0.6ml polypropylene microfuge tubes (Axygen scientific, 
USA) 
DNAse-, RNAse-free sterile polypropylene 1.5ml microcentrifuge tubes (Axygen 
scientific, USA) 
EDTA (lavender top) 5ml Vacutainer blood collection tubes (Beston Dickinson,UK) 
Heparinised (green top) 5ml Vacutainer blood collection tubes (Beston 
Dickinson,UK) 
A2. Solutions 
A2.1 TBARS Assay reagents  
Butylated hydroxyltoluene (BHT) (Sigma-Aldrich Corporation St. Louis, MO, 
United States of America) 
Ortho-phosphoric acid (Sigma-Aldrich Corporation St. Louis, MO, United States of 
America) 
2-Thiobarbituric acid (Sigma-Aldrich Corporation St. Louis, MO, United States of
America) 
Ethanol (Merck chemicals (Pty) Limited, Gauteng, Republic of South Africa) 
Butan-1-ol (Merck chemicals (Pty) Limited, Gauteng, Republic of South Africa) 
Sodium Hydroxide (Merck chemicals (Pty) Limited, Gauteng, Republic of South 
Africa) 
Sodium Chloride (Merck chemicals (Pty) Limited, Gauteng, Republic of South 
Africa) 
Distilled water from ( Redox laboratory, human biology, University of Cape Town) 
100 
4mM BHT in Ethanol: 
Dissolve 0.044g of BHT in 50ml of Ethanol 
0.2M Ortho-phosphoric acid: 
Dilute 0.137 of Ortho-phosphoric acid in 10ml of distilled water 
TBA: 
Make 0.1M of NaOH by dissolviving 0.8g of NaOH in 200ml of distilled water 
Add 0.198g TBA in 12.5ml of the 0.1M NaOH 
A2.2 Vitamin C Assay ( Ferric Reducing Ascorbate Assay) 
Assay done using commercial Ferric Reducing Ascorbate (FRASC) assay kit 
(Catalog #K671-100) by BioVision Research Products (CA 94043 USA) using 
prescribed kit protocol. 
A2.3  ELISA for soluble vascular cell adhesion molecule (sVCAM-1) 
The ELISA for VCAM-1 was performed using a commercial human VCAM-1 
ELISA kit (RayBiotech Company, GA 30092, USA) using prescribed kit protocol.  
A2.4  Enzyme linked immunosorbent assay (ELISA) for E-selectin 
The ELISA for E-selectin was performed using the Human E-selectin ELISA kit 
(RayBiotech Company, GA USA) using prescribed kit protocol. 
A3. Equipment 
Digital Dry Bath (Labnet International, Inc, USA) 
ELISA plate reader (Biotek Instruments, USA) 
Eppendorf centrifuge 5415C (Germany) 
Finnpipette digital multi-channel (50-300µl) (Lab Systems, Finland) 
Hermle Z100M pulser (Labnet international Inc, Korea) 
Refrigerated tabletop centrifuge Hermle Z233 MK-2 (Labnet international Inc, 
Korea) 
Refrigerated Hermie Z233 MK-2 tabletop centrifuge (Labnet international Inc, 
Korea) 
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Shaker type 3005 (GFL, Germany) 
Tabletop Heraeus labofuge centrifuge (Heraeus Sepatech, Germany) 
Tabletop microcentrifuge (Labnet international Inc,Korea) 
Vortex Genie 2 (Scientific industries Inc,USA) 
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APPENDIX B 
B1. Patient information and informed consent document 
Patient information and informed consent document for the study entitled: 
“Vitamin C status, oxidative stress, hyperglycaemia and endothelial function in 
critically ill patients with septic shock: an observational study” 
Investigators:  
Lauren Hill*, Kondwani Katundu*, Fahima Adams*, Lester Davids 
Division of Human Nutrition, Department of Human Biology, University of Cape 
Town 
Ivan Joubert, Lance Michell, Malcolm Miller, Jenna Piercy 
Division of Critical Care Medicine, University of Cape Town 
You are invited to take part in a research study which is being done in the Intensive 
Care Units (ICU) at Groote Schuur Hospital. The study is about vitamin C levels in 
patients who have septic shock (severe infection together with very low blood 
pressure). You are being asked to take part in this study because you have been 
looked after in the ICU where you were treated for septic shock during your stay in 
hospital. While you were extremely sick in ICU, some blood samples were taken 
from you and stored in the freezer for research purposes. Some of the medical 
information about your health and your recovery in ICU has also been recorded for 
research. This information includes your blood sugar, blood pressure, the nutrition 
you received in ICU, and whether you had any organ failure during your illness. All 
of this information was recorded routinely every day by nursing staff, as part of 
normal nursing care. The collection of these blood samples and medical information 
did not put you at any disadvantage in terms of the medical care you needed to 
recover from being in ICU. Now that you have recovered from your illness, we are 
asking you to consider giving us permission to use these stored blood samples and 
the medical information for research.  
What is this study about? 
When a person is extremely sick in ICU, the body naturally seems to become 
deficient in certain nutrients, including vitamin C. Vitamin C is known as an 
antioxidant vitamin. This means that part of its normal functions in the body is to 
neutralise substances that can be damaging to cells. These cell-damaging substances 
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(called free radicals) are produced in tiny amounts during normal chemical reactions 
in cells; and in healthy people, they are quickly removed and kept under control by 
nutrients, such as vitamin C. However, in severe illness, free radicals can be 
produced in larger amounts, as part of the body’s natural response to being sick. This 
makes us think that the body has a high need for vitamin C during times of severe 
illness. In addition, we think that having low vitamin C levels during severe illness 
may cause the small blood vessels of the body to function more poorly. This might 
make it more difficult to treat the very low blood pressure that develops in septic 
shock, and may cause complications of severe illness, such as failure of the organs 
like the kidneys and the lungs.  
What are the tests to be done for research? 
In this study, we are interested in measuring the levels of vitamin C in the blood of 
patients who have had septic shock – to confirm that the body does become deficient 
in this vitamin. At the same time, we would like to measure the amounts of free 
radicals that are present, as well as the blood markers that tell us how well the small 
blood vessels function. While you were in ICU about 3 teaspoons of blood were 
collected from you every day. during the time your blood pressure was very low 
(shock). We now ask your permission to analyse this blood. In addition, we would 
also like to take blood samples from you (about 3 teaspoons each time) once a week 
until you are discharged from hospital for the same blood tests. We are able to 
extract the DNA (material in cells containing your genes) from the blood samples. 
We would also like to keep this DNA for future research on how your genes may 
allow free radicals to form in larger amounts during illness. We will not use your 
DNA for any other purpose. If you would prefer it, we will not save your DNA for 
future study. If you request that we do not save your DNA you can still take part in 
the rest of the study, if you so wish.  
What are the risks and benefits to me if I take part in the research? 
This study is only about measuring the vitamin C, free radicals and blood vessel 
function from blood samples. When blood is taken from you, there might be some 
discomfort, and you may be left with a bruise over the vein. Apart from this, taking 
part in this study cannot negatively affect your health or put you at risk.  
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There is also no benefit to you in taking part in the study. The information we learn 
about vitamin C from testing your blood, might in the future help other patients with 
severe illness and septic shock in ICU by helping us decide whether vitamin C 
should be supplemented during illness.  
Do I have to pay for the blood tests? 
You do not have to pay for any of the blood tests for research (vitamin C, free 
radicals and blood vessel tests). You will also not be given any payment for taking 
part in this study.  
Do I have to take part in the research study? 
No, it is your own choice to take part in this study. If you agree to participate, the 
blood samples already stored will be analysed; and new blood samples will be taken 
once a week until you leave the hospital. We will also follow you while you are in 
hospital and document your recovery or any medical complications you may 
develop. If you decide not to take part in this study, your blood samples already in 
storage will be destroyed – without being analysed. All the medical information that 
has been recorded from your folder for research will also be destroyed. If you choose 
not to take part in the study, you will still receive any medical care you need.  
Will my information be kept confidential? 
Yes, all information and research test results will be kept confidential by the study 
team. Additionally, all the information and results will be labelled with a code, 
instead of your name, so that your identity is also protected. Only members of the 
study team will have access to this information. No information that could identify 
you will be used in publishing the results of the research.  
Are my rights protected? 
This study has been approved by the Human Research Ethics Committee of the 
Faculty of Health Sciences, whose role it is to ensure that patients are not put at 
unnecessary risk during research studies. If you are concerned about your rights, as a 
research participant, you can make contact with this committee as follows: Prof. 
Marc Blockman; Chair: Human Research Ethics Committee, phone: 021 406 6626.  
105 
If you have any questions about the study itself you can speak to any member of the 
research team that comes to see you in hospital. You can also phone Dr Lauren Hill 
on 021 4066769.  
In the very unlikely event that you suffer an injury as a direct result of this study, you 
are covered by an insurance policy held by the University of Cape Town.  
If you agree to take part in this study, please sign the section below:  
I ______________________________________ (name) understand that while I was 
in ICU I became eligible for a research study, and that blood samples for research 
purposes are in storage. I now confirm by signing below that I take part in this study 
of my own free will, and I agree that the blood samples and medical information 
stored for research may be used. I have had all my concerns and questions answered 
to my complete satisfaction. I have had enough time to carefully consider my 
participation, and to document my continued participation with my signature. 
I understand that my DNA (material in my cells containing my genes) has also been 
extracted from my blood samples, and is in storage for possible future research on 
the balance of free radicals in the body.  
I agree that DNA from my blood may be kept in storage for future research only on 
the same topic (about free radicals)         
I do not want my DNA to be stored for future research (if you mark this box you can 
still take part in the rest of the study if you wish)          
Signature of participant_____________________________ Date: _______________ 
Name and signature of researcher performing consent procedure: 
________________________________________________ Date:_______________ 
Name and signature of witness (if applicable): 
_________________________________________________Date: ______________ 
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If you do not agree to take part in this study, please sign the section below:  
I ______________________________________ (name) understand that while I was 
in ICU I became eligible for a research study, and that blood samples for research 
purposes are in storage. I do not wish to participate in this study, and confirm by 
signing below that I want the blood samples and medical information stored for 
research to be destroyed. 
Signature of participant_____________________________ Date: _______________ 
Name and signature of researcher performing consent procedure: 
________________________________________________ Date:_______________ 
Name and signature of witness (if applicable): 
_________________________________________________Date: _____________ 
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B2. APACHE II score 
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B3. The SOFA score calculating sheet 
Organ System Score 
0 1 2 3 4 
Respiratory: 
PaO2/FiO2 




















































15 13-14 10-20 6-9 <6 
For SOFA score: PO2 : FiO2 ratio convert PaO2 in kPa to mmHg by multiplying by 7.5 
Use FiO2 as decimal e.g. if PaO2 = 8kPa, Convert to mmHg = 8x 7.5 = 60mmHg if FiO2 = 0.4 
60 / 0.4 = 150 
a 
Adrenergic agents administered for at least one hour (doses given are in µg/kg per minute). FiO2, 
fractional inspired oxygen; MAP, Mean arterial pressure; PaO2, SOFA, Sequential Organ Failure 
Assessment 
(Doig et al., 2004). 
